

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: A systematic review of passive exposure to cannabis.

Authors: Berthet A, De Cesare M, Favrat B, Sporkert F, Augsburg M, Thomas A, Giroud C

Journal: Forensic science international

Year: 2016 Dec

Volume: 269

Pages: 97-112

DOI: 10.1016/j.forsciint.2016.11.017

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

A Systematic Review of Passive Exposure to Cannabis

Aurélie Berthet^{*a}, Mariangela De Cesare^b, Bernard Favrat^{c,d}, Frank Sporkert^c, Marc Augsburg^c, Aurélien Thomas^c, Christian Giroud^c

^aInstitute for Work and Health (IST), Universities of Lausanne and Geneva, Lausanne, Switzerland

^bUnità di Medicina e Psicologia del Traffico, Lugano, Switzerland

^cUniversity Centre of Legal Medicine, Universities of Lausanne and Geneva, Lausanne, Switzerland

^d Department of Ambulatory Care and Community Medicine (Policlinique Médicale Universitaire), Lausanne University Hospital (CHUV), Lausanne, Switzerland

* Corresponding author:

Tel. +41 21 314 74 68

E-mail: aurelie.berthet@hospvd.ch

1 **Abstract**

2 Passive exposure to cannabis smoke may induce effects on behavior and psychomotor skills,
3 and have legal consequences, including the risk of being falsely considered as a cannabis user.
4 This can become a concern, especially in occupational contexts or when driving vehicles. In
5 order to enable a differentiation between a passive and an active exposure to cannabis and to
6 limit the likeliness to be detected positive following passive exposure, this review identified
7 specific biomarkers of passive exposure in urine, blood, oral fluid, hair, and sebum. Out of 958
8 papers identified on passive exposure to cannabis, 21 were selected. Although positive tests
9 had been observed in all matrices following extremely high passive exposure, some distinctive
10 features were observed in each matrix compared to cannabis active use. More specifically, in
11 everyday life conditions, 11-nor-delta-9-THC-carboxylic acid (THC-COOH) urinary level should
12 be detected below the positivity threshold used to confirm active smoking of cannabis,
13 especially after normalization to creatinine level. Measuring delta-9-tetrahydrocannabinol (THC)
14 and THC-COOH in blood is an appropriate alternative for appraising passive exposure as low
15 and very low concentrations of THC and THC-COOH, respectively, should be measured. In hair,
16 oral fluid (OF) and sweat/sebum emulsion, no THCCOOH should be detected. Its presence in
17 hair argues for regular cannabis consumption and in OF or sweat for recent consumption. The
18 experts should recommend to persons who have to demonstrate abstinence from cannabis to
19 avoid heavily smoky and unventilated environments.

20

21 **Keywords**

22 Passive exposure, cannabis, urine, blood, oral fluid, hair

23 **Introduction**

24 Cannabis passive smoking referred to the inhalation of cannabis smoke, called secondhand
25 smoke or environmental cannabis smoke, by persons other than intended "active" smokers. It
26 occurs when cannabis smoke contaminates any environment and it is inhaled by people staying
27 in that environment. Secondhand smoke is defined as the combination of the sidestream smoke
28 released from a burning end of a marijuana cigarette and the mainstream smoke exhaled by a
29 smoker [1]. Besides inhalation, unintentional cross-contamination could also occur by
30 unintended direct contact with contaminated objects, as illustrated in Figure 1. Hence, cannabis
31 smoke can be swallowed or deposited on hair, skin, clothes, and surrounding surfaces (e.g.,
32 furniture, doorknobs or water taps) [2]. This type of pollution is called thirdhand smoke [3].
33 However, the cross-contamination and exposure of non-smokers should happen less frequently
34 than self-contamination, despite the fact that residual cannabinoids may build up on surfaces
35 over time and resist normal cleaning and airing out [4]. Lastly, cannabis derivatives may be
36 accidentally ingested with contaminated food.

37 Several studies evidenced detectable concentrations of cannabinoids in body fluids following
38 exposure to secondhand cannabis smoke [5-23]. For instance, the recent studies by Herrmann
39 et al. [10] and Cone et al. [8; 9] confirmed that passive exposure to cannabis smoke under
40 extreme exposure conditions not only resulted in measurable cannabinoid concentrations in oral
41 fluid, blood, and urine, but also in minor physiological (increased heart rate) and subjective drug
42 effects, as well as minor impairments in a task requiring psychomotor ability and working
43 memory. This exposure could be very common (e.g., one partner smoking marijuana, to sit in a
44 car or stay at home with one or several smokers).

45 Passive exposure to cannabis is furthermore a significant legal issue, and it may be especially
46 so in occupational contexts and when driving vehicles. In the workplace, passive exposure
47 should not be mistaken for active use if it might lead to sanctions against employees. With
48 regard to driving, active and regular cannabis consumption should not be mistaken for
49 unintended frequent passive exposure. In cases of acute exposure and a zero-tolerance driving
50 policy, a THC-positive blood specimen may well result in the same legal and administrative
51 consequences, regardless of whether exposure was active or passive. In the forensic and
52 medical contexts, differentiating passive, unintentional exposure to cannabis remains an issue
53 of how to interpret the results of body fluid analyses.

54 Most experimental studies assessing the importance of passive contamination to environmental
55 cannabis smoke were carried out with abstinent volunteers enclosed in an exposure chamber.

56 Many parameters were controlled as the smoke density, the cannabinoid concentrations, or the
57 duration of exposure. From these studies, the present review summarizes findings obtained until
58 December 2015, and discusses the relevance of the different biomarkers available for diagnosis
59 of passive exposure *versus* active use. More specifically, it describes the current state of
60 knowledge on the passive inhalation of cannabis, and the consequences of an external
61 contamination of body surfaces on the results from tests of biological samples (urine, blood, oral
62 fluid, hair, and sebum/sweat). The specific biomarkers and decision limits, or positivity
63 thresholds, that can help differentiate between active consumption and passive exposure will
64 particularly be discussed from a legal and forensic perspective. After a short presentation of the
65 most important factors affecting the cannabis contamination, the selection strategy of the
66 relevant scientific literature will be described. The paper will afterwards consider the important
67 elements (i.e., analytical methods, concentration ranges, contamination, and interpretation) in
68 result interpretation of each biological fluid and tissue following passive exposure to cannabis.

69 This review article is mainly intended for forensic experts who are confronted with statements of
70 passive contamination or for persons frequently exposed and worried by passive cannabis
71 smoke. This article should allay some of their concerns and facilitate the work of expertise of
72 forensic experts.

73

74 **Cannabinoids: metabolism in human**

75 The plant precursor to THC is delta-9-tetrahydrocannabinolic acid A (THC-A) [24]. THC-A itself
76 has no psychotropic effect and should be considered as a pro-drug. The main active
77 cannabinoid responsible for the psychoactive properties of cannabis is THC [25]. The thermal
78 decarboxylation of THC-A to THC is only partial when cannabis is smoked [26] or rarely
79 complete when heated in an oven. Although it is mainly inhaled, cannabis can also be
80 consumed in food and beverages. As medicine, cannabis is generally not smoked (but can be
81 vaped); the risk of passive contamination is thus very low.

82 Cannabinoids can be absorbed by respiratory airways and to a lesser extent by oral route. The
83 dermal route was reported to be minor; therefore, a passive contamination by this route seems
84 unlikely [27]. After inhalation, THC is rapidly absorbed from the lungs into the bloodstream. It is
85 metabolized by liver enzymes or distributed to adipose tissue, the lungs, and spleen due to its
86 high lipophilicity [25]. In the liver, THC is oxidized mainly into 11-hydroxy-delta-9-THC (11-OH-
87 THC) and then into 11-nor-delta-9-THC-carboxylic acid (THC-COOH) [28]. THC-COOH is

88 further rapidly conjugated to glucuronic acid, forming the ester-link glucuronide (THC-COOH-
89 glucuronide). THC is slowly released from the body's lipid-storage compartments. THC's
90 plasmatic terminal half-life is estimated at 1 to 6 h for infrequent users and 20 to 36 h for
91 frequent users [29-31]. THC is eliminated slowly, mainly in the form of acid metabolites, and its
92 main disposal route is via feces (60%–80%); the urine route is less important (20%–35%). In
93 urine, the main metabolite excreted is THC-COOH-glucuronide. Only a small amount of free
94 THC-COOH is excreted (< 4%), along with only traces of THC. The urinary excretion half-life of
95 THC-COOH was estimated at 30 h by Musshoff and Madea [25] to 3 to 4 days by Huestis et al.
96 [30], depending on cannabis conditions of use.

97

98 **Cannabis smoke**

99 Overall, it is the smoking of cannabis cigarette that raises a number of questions regarding the
100 passive exposure to cannabinoids, and more specifically to THC. In an attempt to estimate
101 inhaled THC doses and to determine an internal dose, some studies monitored THC levels in air
102 [5-7; 14; 18; 19]. It is assumed that the smoking process itself degrades 23%–30% of the total
103 THC content in cannabis by pyrolysis, and some 20%–37% is delivered to the active user in
104 mainstream smoke. The remaining 40%–50% of THC is released to the environment in
105 sidestream smoke [18; 25; 32; 33]. Consequently, despite the high influence of several factors
106 on the rate of absorption, a notable amount of THC can still be inhaled by passive smokers and
107 then be absorbed, metabolized, and excreted just like an active user.

108 Until recently, few investigations have been carried out to characterize the components of the
109 smoke from marijuana cigarettes, and the majority of these concentrated on analyzing the
110 cannabinoids in smoke, as they are the most biologically active constituents of cannabis [34].
111 Cannabis smoke is composed of gas and particulate phase substances. Cannabinoids are
112 mainly found in the particulate phase [35]. This smoke is diluted in the environment, and low but
113 notable concentrations of THC and other cannabinoids can be measured in several urban areas
114 [36; 37].

115

116 **Influence of experimental conditions**

117 The studies on passive exposure to cannabis smoke clearly evidenced the importance of the
118 different factors influencing the results and their interpretation. In 1983, Falck [38] highlighted
119 the many factors influencing concentrations of urinary cannabinoids: amounts of water drunk

120 before urine collection, the rate of urine formation, metabolic rate, the quantity of urine voided,
121 and the time of marijuana absorption or urine voiding. Similarly, Cone and Johnson [5] pointed
122 out that plasma levels and the presence of urinary metabolites depended on a variety of factors,
123 including duration and frequency of exposure to smoke, cannabinoid concentrations in the
124 room's air, and individual sensitivity to marijuana. According to Moffat [31], the most important
125 factors influencing body fluid concentrations were: smoking techniques (i.e., THC content, room
126 size, ventilation, exposure time, the number of smokers in the room, the time between exposure
127 to passive smoke and urine collection, and urine hydrolysis to obtain the free acid in order to
128 increase the sensitivity of metabolite detection. Busuttill et al. [39] added dose (the amount of
129 THC released in smoke), body weight, age, sex, renal and hepatic function, and the analytical
130 techniques used as factors affecting the detection of THC and its metabolites in blood and urine.
131 Furthermore, the studies by Niedbala et al. [17-19] confirmed that the detection of THC-COOH
132 in urine (in free and conjugated forms) is affected by a multitude of pharmacological and
133 physiological factors (i.e., THC content of marijuana, dose uptake, sampling time, individual
134 renal and metabolic characteristics, body size). In addition, methods of cannabis inhalation can
135 also modify exposure levels for non-smokers [40].

136

137 **Biological markers and decision limits as criteria of passive exposure**

138 Since 1977, several authors have studied passive exposure to cannabis smoke in order to
139 better interpret analytical results and to validate the decision limit or positivity threshold fixed by
140 different scholarly societies (see Table 1). However, as no standard definition of “passive
141 inhalation” exists, concerns remain to diagnose active use or passive exposure based simply on
142 levels in body fluids [39; 41]. From a forensic viewpoint, Busuttill et al. [39] defined passive
143 exposure as “the presence of cannabinoids in the body fluids of non-users who have been
144 passively exposed to marijuana smoke”. The authors pointed out that any person who allows
145 himself to be deliberately exposed to cannabis smoke—at high dosages, for long durations, and
146 in a confined space, so as to absorb enough THC for metabolite levels to be measured at over
147 100 ng/mL in urine (total THC-COOH, without correction for creatinine) or 25 ng/mL in plasma
148 (free THC-COOH)—must be a “willing participant” and knowingly aware of the potential effects
149 [39]. Consequently, the concept of passive exposure involves unintended contamination.
150 Moreover, THC in sidestream smoke is mainly released as aerosol particles and their
151 concentration is rapidly and heavily diluted with the flow of surrounding air [19]. It remains that
152 over the last few decades, the levels of THC in plants have raised substantially, mainly due to

153 the expansion of indoor cultivation and the selection of varieties that maximize THC yields [8;
154 29] (e.g., the average potency of all types of cannabis was 13.2% in 2012 vs 2.8% and 7.3% for
155 marijuana and sinsemilla, respectively, in 1985 in the US [8], and remained unchanged for 10–
156 20 years, consistently 2%–8%, to reach more than 10% in Europe [42]). Consequently, the
157 higher the potency of the cannabis is, the greater the potential risk of positive body fluid test
158 results after passive exposure.

159

160 **Selection strategy of references**

161 Several library databases were used to identify and select publications dealing with passive
162 exposure to cannabis (i.e., PubMed, Medline Ovid SP, Embase, Cochrane Library Wiley,
163 Cinahl, Web of Science and Google Scholar). Only papers published after 1970 and before
164 August 2015 were considered. Different terms and research strategies were combined (see
165 supplementary data for the combinations of search terms used). The selection was based on
166 titles and abstracts, and papers in English, French, German, and Italian were considered. The
167 initial investigation identified 958 papers; after removing duplicates and considering the
168 suitability and appropriateness of titles, 98 abstracts were reviewed. Of these, 77 papers did not
169 fulfill the criteria for eligibility. These criteria included only studies on exposure to passive
170 cannabis smoke in controlled conditions, collecting biological matrices in non-users volunteers,
171 and reporting results on matrix analysis. A final total of 21 studies on passive exposure to
172 cannabis were selected. In agreement with Moffat [31], the authors of this review considered
173 that the most important factors in each study were:

- 174 1. Volume of the exposure room and its ventilation characteristics (e.g., opening a
175 door or window can reduce the concentration of THC in the air);
- 176 2. Number of non-smoker volunteers exposed to passive inhalation of cannabis;
- 177 3. Exposure time and exposure conditions for the non-smoker volunteers;
- 178 4. Magnitude of exposure (e.g., number of marijuana cigarettes smoked, dose of
179 THC);
- 180 5. Analytical methods used to detect the cannabinoids and their metabolites in body
181 fluids and tissues.

182 The 21 publications included in the present study are summarized in Supplementary Tables 1
183 and 2.

184

185 **Biological samples: methods of analysis, concentration ranges after passive exposure**
186 **compared to active use, result interpretation, and decision limits**

187 Environmental exposure to cannabis smoke can be detected and analyzed in urine, blood, oral
188 fluid, hair, and sebum/sweat. Each biological specimen provides different information regarding
189 the drug's effects on health, performance, behavior, and on the individual's drug-exposure
190 history. Likewise, each matrix has its specificities with regard to interpreting cannabis exposure,
191 offering different advantages and disadvantages for drug testing. Figure 2 summarizes the main
192 potential markers present in the different biological matrices, as well as their excretion routes
193 following the involuntary exposure to cannabis.

194

195 **Urine**

196 Urine remains the matrix of choice for drug-testing programs to demonstrate past drug exposure
197 in workers or drivers because of the long time detection of THC-COOH and its conjugated
198 metabolite in urine. One of the major advantages of using urine as a matrix is the ease to collect
199 spot samples at any time (determined collection time or ad libitum collection) from an analytical
200 point of view. However, urine samples imply large variability in volume and, consequently, in
201 chemical concentrations from void to void [43]. In addition, urine samples can be falsified by
202 dilution, substitution, or adulteration using a wide array of substances.

203

204 *Analysis*

205 Urine is mainly analyzed using immunoassays and chromatography coupled to mass
206 spectrometry methods. Regarding immunoassays, improvements in method sensitivity and
207 specificity as well as more appropriate enzymes allowed selection of a lower cut-off to
208 distinguish active from passive smoking and to develop a less invasive body fluid collection. As
209 illustrated in Table 2, the enzyme multiplied immunoassay technique (EMIT) was first commonly
210 used, but the labeling of antibodies was changed to decrease the limit of detection (LOD) value,
211 and EMIT was replaced by ¹²⁵I-radioimmunoassay (RIA, 2 ng/mL) or enzyme-linked
212 immunosorbent assay (ELISA, 0.6 ng/mL). RIA had the advantage that no cross-reaction with
213 other compounds than cannabinoids related to $\Delta 8$ or $\Delta 9$ was observed, reducing the risk of
214 false positive results [13; 31]. Although immunoassays are considered as suitable methods for
215 cannabinoids screening, some limits are recognized, such as cross-reaction with related and
216 unrelated compounds (inducing false-positive results) or generation of artifacts in the presence

217 of adulterants affecting matrix pH, presence of detergents or surfactants (inducing false-
218 negative results) [25; 29]. Therefore, immunoassays are commonly adopted as a preliminary
219 test method while mass spectrometry based methods are currently used to confirm cannabinoid
220 identity and assess cannabinoid levels [25; 31]. Nowadays, the single chromatography coupled
221 to mass spectrometry (GC-MS) methods are replaced by two-dimensional gas-chromatography
222 high resolution mass spectrometry methods or ultra high performance liquid chromatography
223 interfaced with atmospheric pressure ionization coupled with tandem high resolution mass
224 spectrometry (LC-MS/MS). This last method short-circuits the extraction step and allow the
225 direct analysis of free THC-COOH and its glucuronide conjugates in urine [44]. In contrast, GC-
226 based methods require the hydrolysis of conjugates and a derivatization step before analysis.
227 Results are expressed as total THC-COOH (free plus conjugated).

228 The best means of reducing drug measurement variability is to normalize cannabinoid
229 concentrations to the urinary creatinine level. The normalization also allows the monitoring of
230 abstinence from cannabis use and reduces false-positive or false-negative drug tests, especially
231 during the late elimination phase when concentrations are either just above or below threshold
232 values [30; 45-47]. Consequently, it is recommended to take into account the creatinine
233 concentration for urinary THC-COOH although the decision limits or positivity thresholds are
234 fixed without creatinine correction. In serial urine specimens, creatinine-normalized THC-COOH
235 concentrations are also considered as better indicators to predict reuse of marijuana than
236 without creatinine normalization [48].

237

238 *Concentration ranges*

239 The detection of cannabinoids in urine indicates a past exposure to cannabis. However, urine
240 gives no information related to the exposure route, the duration of exposure, or the amount of
241 cannabis absorbed because of the long excretion half-life and the wide inter-individual variability
242 [17; 30; 49]. Figure 3 summarizes the concentrations adjusted for creatinine of THC-COOH time
243 profile in urine of different studies during and following a passive exposure to cannabis. Only
244 studies analyzing urine by GC-MS and adjusting by creatinine were considered in Figure 3.
245 Hence, in passive exposure studies, THC-COOH can be detected in urine around 1 h after
246 exposure, and peak THC-COOH concentrations are observed at 6 to 8 h after exposure.
247 Nevertheless, according to Westin and Slordal [49], any measurement of THC and THC-A, or of
248 cannabinoids above the limit of quantification (15 ng/mL for THC-COOH, without correction for
249 creatinine) in the urine of passive smokers must be related to such an extremely high exposure

250 that the person concerned could not be unaware that smokers in the immediate vicinity were
251 smoking cannabis. Figure 3 supports a limit value of 15 ng/mg of creatinine for THC-COOH;
252 higher values were obtained in extremely high exposure conditions. As no mandated creatinine-
253 normalized thresholds are available, Schwilke et al [48] have developed empirically derived
254 statistical models using limit concentration values of 15 and 6 ng/mg creatinine as cutoffs to
255 distinguish abstinence from new cannabis use in chronic smokers. These cutoffs are similar to
256 the limit value observed in Figure 3.

257

258 *Interpretation*

259 The interpretation of urinary results is complex, and several factors may influence urinary
260 concentrations of the main metabolite, THC-COOH-glucuronide. In addition to creatinine
261 normalization, individual variability, and exposure conditions (cannabis dose and number of
262 smokers, design of the room), the exposure room's ventilation appears to be a relevant factor to
263 consider. According to the study of Cone et al. [8], for the same inhaled dose of cannabis, total
264 THC-COOH concentrations in the urine of passive non-smokers was two-thirds lower when the
265 room was ventilated (median maximum concentration, or C_{max} , of 24.9 and 8.5 ng/mL THC-
266 COOH (30.8 and 9.1 ng THC-COOH/mg creatinine, respectively) without and with ventilation,
267 respectively). Cone et al. [8] also noticed similar differences for THC-COOH levels in the last
268 collected urine specimen (4 ng/mL (6.7 ng THC-COOH /mg creatinine) versus 1.2 ng/mL (2.4 ng
269 THC-COOH /mg creatinine) in a ventilated room, 31 h after exposure). In studies with
270 ventilation, C_{max} was found to be slightly delayed to 6 h, compared to the 4 h observed in
271 studies with poor or no ventilation (see Figure 3). Besides ventilation effects, the range of THC
272 concentrations has been correlated with the potency of marijuana cigarettes. Elimination time
273 profiles shifted to greater concentrations when potency or dose was increased, but their time-
274 appearance remained very similar across the whole experiment. Consequently, urinary
275 concentrations are mainly dose-dependent [12]. Further, the choice of the positive threshold
276 value and the screening test characteristics will greatly influence the rate of positive sample
277 detection. Hence, Cone et al. [8] found that increasing the immunoassay cut-off from 20 ng/mL
278 to 50 ng/mL significantly decreased the rate of positive presumptive urine tests in non-smokers.
279 At a 50 ng/mL cut-off, all but one of the immunoassays included in the experiment provided
280 negative results. In summary, urine is an appropriate matrix to monitor abstinence from
281 cannabis after creatinine normalization, even after moderate second-hand smoke exposure. In
282 extreme conditions, THC-COOH may be detected in urine after passive exposure to cannabis

283 smoke. However, ventilation strongly attenuates the likelihood of being tested positive, and
284 urinary concentrations of cannabinoids are greatly influenced by the potency of the marijuana
285 and the dose.

286 **Blood**

287 Blood analyses are necessary for the detection of recent exposure to cannabis or for the
288 evaluation of its effects on behavior and performance [9; 10]. In general, as THC is extensively
289 bound to lipoproteins, the preferred specimens for blood analyses are plasma or serum. The
290 two main metabolites considered as detectable in blood specimens after passive exposure are
291 THC-COOH and its glucuronide ester conjugate [39].

292

293 *Analysis*

294 The majority of passive exposure experiments involving THC measurements in plasma were
295 performed in the 1980s. At that time, blood analyses were carried out using a
296 radioimmunoassay or, less frequently, single-quadrupole gas chromatography–mass
297 spectrometry (GC-MS). RIA was the main radioimmunoassay method for plasmatic THC
298 determination (cutoff of 3 ng/mL). However, due to cross-reactions of antibodies with
299 metabolites in a radioimmunoassay, it is difficult to compare these estimates with the results
300 obtained using modern mass spectrometry techniques. As for urine, immunoassays are
301 considered as a preliminary test method and results have to be confirmed using mass
302 spectrometry based methods. However, highly sensitive and accurate methods are required to
303 detect and quantify the low blood concentrations of THC observed during the late time course of
304 drug effects due to THC's rapid distribution to bodily tissues and to the time delay between
305 exposure and sample collection [30; 50; 51]. Hence, more recently, Röhrich et al. [22] and Cone
306 et al. [9] used more sophisticated mass spectrometry assays (e.g., liquid chromatography
307 interfaced with tandem MS) either with serum or whole blood, and managed to extend the time
308 since exposure in which cannabinoids can be measured accurately (Table 2).

309 To accurately compare concentrations detected in blood specimens, the distribution ratio of
310 cannabinoids between plasma or serum and whole blood should also be considered. A mean
311 plasma to whole blood ratio of 1.6 has been suggested for both THC and THC-COOH [52].
312 Nonetheless, contrary to urine with creatinine, normalization with hematocrit is hardly ever done
313 for blood, serum, or plasma. Hematocrit values are systematically ignored, although they vary
314 substantially between whole blood specimens. Likewise, the small fraction of free cannabinoids

315 ables to bind to brain receptors and to induce the typical effects of cannabis is never evaluated
316 either. Nevertheless, with the recent development of deuterated homologs and specific
317 quantification methods, it is now possible to analyze free and conjugated cannabinoids
318 separately. These two values should therefore be quantified to give a better interpretation of
319 results.

320

321 *Concentration ranges*

322 Cannabinoid kinetics in blood are complex and difficult to interpret. Figure 4 summarizes the
323 concentrations of THC (a) and THC-COOH (b) time profile in blood of different studies during
324 and following a passive exposure to cannabis. The results of Morland et al. [15] showed that the
325 highest levels of plasmatic THC were measurable immediately after the three volunteers had
326 been exposed to 30 min of secondhand smoke generated by two smokers in a small car.
327 Despite only two sampling times in this study, it can be assumed that the levels of plasmatic
328 THC measured in blood just after leaving the car were close to the maximum values, as it has
329 been observed in more recent studies (Figure 4a). At 2 h, THC levels had decreased to
330 insignificant values. However, the use of low-potency marijuana cigarettes (1.5% THC) highly
331 limits the relevance of this study today. Currently, cannabis is far more potent, and the
332 composition of the different cannabinoids in cannabis plants has diversified. For instance, some
333 plant strains may be characterized by a high proportion of THC and cannabidiol (CBD) (e.g.,
334 10% THC and 15 % CBD), whereas others have a high content of tetrahydrocannabivarin
335 (THCV). THCV is a THC variant with short C3 lateral chain reported to have psychoactive
336 properties at high doses (e.g., Perplex Feminized Seeds marketed by Seed Supreme) [53]. For
337 the recent studies by Röhrich et al. [22] and Cone et al. [9], comparing Figures 4a and 4b
338 reveals similar ranges of THC and THC-COOH concentrations, as well as similar C_{max} (at T_{max}
339 between 20 to 60 min) for both compounds. Concurrent measurements of THC and THC-COOH
340 in whole blood after passive exposure indicated a rapid absorption and metabolism of THC.
341 However, Röhrich et al. [22] detected very low concentrations of THC and THC-COOH in
342 passive smokers at the end of exposure. Indeed, they were so close to the analytical cut-off that
343 calculation of their relative levels was irrelevant. The maximum THC concentration was
344 observed at 90 min after the beginning of the exposure, and undetected 180 min after exposure
345 to cannabis smoke. The exposure scenario conditions selected for non-smoker volunteers in
346 this study seemed closer to real passive smoking conditions than the 1980s studies (e.g., large
347 room, efficient ventilation, quite a long exposure time (3 h), and between 8 and 25 cannabis

348 users). In the study by Cone et al. [9], the range of reported C_{max} levels over the three sessions
349 was 0.5–3.1 ng/mL for THC and 0.2–2.5 ng/mL for THC-COOH at 0.25 h following the 1 h
350 exposure session. As expected, higher C_{max} were observed in unventilated conditions. It was
351 estimated that active smokers delivered 6%–18% of the dose to passive smokers in an
352 unventilated room, and this decreased with ventilation. At these estimated cannabis doses,
353 volunteers reported some of the typical psychoactive effects of cannabis. However, the effects
354 due to THC exposure remain difficult to interpret in the absence of a placebo session.

355

356 *Contamination*

357 In order to avoid direct contamination, it is recommended that blood specimens should be
358 collected outside the contaminated place or room and that butterfly catheters are protected from
359 cannabis smoke in serial blood sample collection. In the earliest studies, the elimination profiles
360 in the plasma from the studies by Perez-Reyes et al. [21] and Mason et al. [54] were not
361 considered in Figure 4a, due to possible contamination and the absence of controls or placebos.
362 In these studies blood sampling only restricted the exposure period and collection occurred
363 inside the exposure room so as to reach a steady-state THC level in volunteers (Supplementary
364 Table 2). Unlike these two studies, Morland et al. [15] collected blood specimens after the
365 exposure period and outside the exposure area in order to reduce the risk of contamination
366 during blood sampling.

367

368 *Interpretation*

369 When interpreting blood results, it is important to consider certain factors other than the
370 complete description of exposure parameters. Goullé et al. [29] interpreted the blood kinetics
371 following inhalation by using a multiphase profile. High plasmatic concentrations of THC are
372 reached within the first minutes of the inhalation phase. This is followed by an initially rapid
373 decrease (distribution phase) and then a slower elimination, implying the use of a multi-
374 compartment pharmacokinetic (PK) model or alternative complex models. The multiphase
375 absorption and elimination time-profile can be inferred from the broad range of early passive
376 smoking studies presented by Cone et al. [5-7]. Volunteers stayed in a closed, unventilated
377 room for six consecutive days and were exposed to 4 or 16 marijuana cigarettes (2.8% THC) for
378 60 min each morning (Supplementary Table 2). Despite the daily repetition of exposure
379 sessions, proof of THC accumulation in plasma remained inconclusive [7]. Nevertheless, the
380 highest mean plasma levels (2.4 and 7.4 ng/mL for 4 and 16 cigarettes, respectively) were

381 indeed observed on the last day of exposure. The exposure conditions of this study were
382 extreme and are unlikely to occur in daily practice (i.e., an unventilated room and 16 marijuana
383 cigarettes smoked for 1 h each day for 6 consecutive days): volunteers had to wear goggles to
384 tolerate the noxious smoky environment.

385 Researchers have been trying to identify the criteria and potential markers able to distinguish
386 active consumption from passive exposure from the very earliest studies on passive cannabis
387 exposure [15; 21; 54]. In this perspective, Mason et al. [54] suggested comparing the
388 concentrations of THC and THC-COOH in plasma; after active smoking, THC is present in low
389 concentrations in the latter part of the elimination curve and THC-COOH levels always exceed
390 those of THC: after passive exposure, THC-COOH concentrations are always lower than THC
391 concentrations. This scenario can be observed by comparing Figures 4a and 4b. Consequently,
392 threshold values for THC-COOH have been proposed for differentiating regular cannabis use
393 from occasional smoking. Blood levels above 40 ng/mL of free THC-COOH strongly suggest
394 regular consumption of cannabis [55; 56]. After passive exposure, Toennes et al. [51] and
395 Röhrich et al. [22] reported THC-COOH concentrations in serum of 2 ng/mL at 1 h after
396 exposure; it was lower than 1 ng/mL for THC. They thus suggested that THC and THC-COOH
397 serum levels higher than 2 ng/mL would imply deliberate consumption. However, it remains
398 unclear whether regular passive exposure over a long period can lead to higher cannabinoid
399 levels.

400

401 Overall, blood is an appropriate matrix to detect recent exposure and evaluate the effects of
402 cannabis on behavior and performance. After passive exposure in extreme conditions, low and
403 very low concentrations of THC and THC-COOH, respectively, should be observed (values
404 should be insignificant 2 h after exposure). To avoid direct contamination of the matrix, sampling
405 must be performed outside of the smoking area.

406

407 **Oral fluid**

408 Oral fluid (OF) is considered a suitable matrix for monitoring recent cannabinoid use or
409 unintentional passive exposure [57]. It is commonly accepted that the presence of THC and
410 THC-A (the plant precursor of THC) in OF is evidence of recent exposure to cannabis [17; 18].
411 The presence of THC-COOH molecules (free and conjugated) is generally considered as the
412 best biomarker to detect active cannabis use as THC-COOH in OF is related to plasmatic
413 concentrations and it is not present in smoke [58]. However, contrary to THC, THC-COOH

414 metabolite can be detected in a glucuronidated form and in very low concentration ranges
415 (pg/mL), requesting more sensitive and up-to-date methods; consequently, most investigations
416 are limited to THC as it is present in very high levels [14; 30; 57; 59; 60]. To increase the
417 sensitivity of THC-COOH detection in OF, recent analytical methods have been developed
418 either for including a preliminary step to hydrolyze THC-COOH-glucuronide or for determining
419 THC-COOH and THC-COOH-glucuronide separately [59; 61; 62]. However, the presence of
420 beta-glucuronidase enzymes in the OF could hydrolyze THC-COOH glucuronide and hamper
421 the detection of glucuronide conjugates [57; 61]. Until now no study has demonstrated the
422 presence of THC-COOH in OF following passive exposure to cannabis smoke [58], THC-COOH
423 alone or in the free and conjugated forms should be monitored in OF to identify active cannabis
424 smoking or in suspicion of active cannabis use.

425

426 *Analysis*

427 OF samples were analyzed by very sensitive, selective and specific two-dimensional gas-
428 chromatography high resolution mass spectrometry methods or by high resolution liquid
429 chromatography interfaced with atmospheric pressure ionization coupled with tandem high
430 resolution mass spectrometry (Table 2). These methods allow a direct analysis of OF without
431 performing extraction previously [63]. Notwithstanding, a GC- or a target LC-MSMS method can
432 be as sensitive as a high-resolution mass spectrometry (HR-MS); however, direct analysis of
433 untreated oral fluid is not really recommended.

434

435 *Concentration ranges*

436 Five studies on the passive inhalation of cannabis smoke monitored THC concentrations in OF
437 specimens. The Figure 5 represents the concentrations of THC time profile in OF of different
438 studies during and following a passive exposure to cannabis. As illustrated in Figure 5, THC
439 C_{max} was observed until 20 min after exposure to cannabis smoke. THC concentrations were
440 then seen to decrease rapidly until 60 min. Niedbala et al. [18] explained the high
441 concentrations observed shortly after passive exposure to cannabis smoke by the fact that up to
442 50% of the total THC content in a cannabis cigarette is released in sidestream smoke.
443 Determining a reliable, accurate C_{max} for cannabinoids using OF specimens is very difficult
444 considering the sampling device's potential for contamination and the rapid decrease in
445 concentrations after passive exposure to cannabis smoke. Actually, the higher THC

446 concentrations observed in volunteers by Niedbala et al. [19] in their study I compared to their
447 study II was probably due to device contamination (Supplementary Table 2). To limit
448 contamination, Moore et al. [14] collected OF outside coffee shops in the Netherlands. However,
449 variations in the number of smokers present inside the coffee shops during the 3-hour exposure
450 period make the results difficult to interpret. This study only highlighted positive test results
451 following passive exposure to cannabis smoke, but no conclusions could be made regarding
452 kinetics or elimination after 3 h of exposure (Figure 5).

453

454 *Contamination*

455 As for blood sampling, to avoid direct contamination, OF specimens must be collected outside
456 the contaminated place or room and sampling devices should be protected from cannabis
457 smoke. Another element to consider as potential contamination is THC accumulation in the
458 mucosa of the upper respiratory tract following active or passive smoking, even though
459 cannabinoids are very poorly excreted in saliva [19; 30]. This contamination may last for 6 to 9 h
460 and can be detected using an adequately sensitive test; however, positive tests are very rarely
461 obtained more than 2 h after the last use [30; 64]. Furthermore, exposure to cannabis inhibits
462 the formation of saliva, resulting in a dry mouth [24] and hampering the collection of OF just
463 after cannabis exposure or smoking.

464

465 *Interpretation*

466 Reliable testing for THC in OF faces some analytical concerns and requires an efficient test
467 system (i.e., collection device, screening procedure, or confirmation assay). Among the most
468 important issues are: i) the potential environmental contamination of the collection devices, ii)
469 the stability of THC and its absorption to the polystyrene surfaces of collection devices, iii) the
470 variability in the design of collection devices, and iv) the potential for false-positive test results
471 following passive exposure if low THC concentrations are measured [14; 17; 30; 57; 64].

472 To bypass these issues, other possible markers have been suggested for detecting active
473 smoking and differentiating it from passive exposure: THC-COOH, THC-A, and other minor
474 cannabinoids. Whether it is possible to detect THC-COOH in OF after long-term passive
475 exposure to cannabis smoke has not yet been evaluated. Consequently, Cone et al. [9]
476 suggested measuring THC-COOH in OF in order to differentiate active cannabis use from
477 passive exposure as no THC-COOH concentrations were detected in non-smoker OF

478 specimens under their three session conditions. Moreover, THC-COOH has never been
479 detected in either cannabis plants or the smoke from cannabis joints. Therefore, THC-COOH is
480 the best-known marker of active cannabis consumption in OF, although the concentration cut-off
481 selected (50 pg/mL) has a significant influence on how frequently it is detected compared to
482 THC [65]. THC-A was also suggested as a marker because most THC/ cannabidiol-based
483 medicines do not contain it. Its presence in OF is therefore probably due to its incomplete
484 decarboxylation [66]. It could also be the result of direct contact between the plant material in
485 the cannabis cigarette and the mouth. It should not be detectable in passive smokers. Lastly,
486 Anizan et al. [67] proposed some minor cannabinoids, the cannabidiol (CBD), and the
487 cannabinol (CBN) as markers of recent cannabis consumption. However, they were only
488 detected when a single brand of cannabis cigarettes was tested, containing no tobacco and a
489 specified proportion of THC and CBD. In addition, the presence of CBD could also be related to
490 the therapeutic administration of a variety of medicinal cannabis [68]. THC, THC-COOH, and
491 THC-A thus remain the main compounds that should be monitored in OF in order to distinguish
492 active exposure from passive exposure to cannabis. A particular carefulness is nonetheless
493 required if blood is present in OF (e.g., in case of bleeding gums) as it can noticeably increase
494 cannabinoid concentrations [69; 70]. Consequently, determination of several cannabinoids may
495 help to interpret concentration results in OF.

496
497 The advantage of OF testing over urine testing is that the presence of THC in OF suggests
498 recent exposure. A fraction of the THC retained in the oral cavity may be passively absorbed
499 into the bloodstream through the mucosa, enhancing THC concentrations in blood [17].
500 Consequently, OF is probably not the most appropriate matrix to demonstrate or evaluate the
501 extent of passive exposure to cannabis smoke.

502

503 **Hair**

504 Hair samples offer some advantages over other matrices: collection is non-invasive and less
505 intrusive than urine or blood, and can be stored at room temperature. Sampling limitations
506 include baldness or short hair [25]. The presence of cannabinoids in hair, especially THC,
507 provides information on repeated or chronic exposure [25; 64].

508

509 *Analysis*

510 To quantify cannabinoids in hair, analytical methods require to detect femto- to picogram
511 residue ranges per milligram of hair [30]. From the end of 1990's, the main analytical methods
512 used to analyze THC in hair was via GC-MS. Recently, THC-A can also be measured in hair,
513 and as for THC-COOH a negative ion chemical ionization mass spectrometry, GC-NCI-MS or
514 GC-NCI-MS/MS is needed [4]. A new approach has also been developed by Duvivier et al. [71]
515 and consists of a longitudinal scanning of THC in hair using direct analysis in real time (DART)
516 ambient ionization orbitrap MS. This method allows to perform a pre-screening test of THC in
517 hair without sample preparation.

518

519 *Concentration ranges*

520 THC is the most common compound measured in hair, followed by CBD and CBN, and THC-
521 COOH [4; 30]. THC and THC-COOH have very low incorporation rates into hair [72]. THC's
522 presence may be explained by its weak bond to melanin, whereas THC-COOH's absence may
523 be due to the acidic nature of hair [4; 25].

524 In the study by Moosmann et al. [73], the highest concentrations in hair for THC, THC-A, and
525 CBN were observed at the end of the passive exposure period, i.e., after an exposure of one
526 joint every weekday for three weeks (17.3 pg/mg for THC-A, 803 pg/mg for THC, and 307
527 pg/mg for CBN; Table 2). THC-COOH in urine was measured twice a week during the exposure
528 period in order to control abstinence in volunteers. Hair analyses for THC-A and THC-COOH
529 could be considered as useful complementary procedures for monitoring active and passive
530 exposure using other matrices. The only exposure to cannabis that the detection of plant
531 cannabinoids in hair (THC-A, CBD, THC-V) excludes is a single oral administration of a
532 therapeutic dose of synthetic THC (dronabinol). THCV (in hair) and its metabolite THCV-COOH
533 (in urine) could be useful markers to differentiate dronabinol intake from exposure to cannabis
534 smoke [74].

535

536 *Contamination*

537 With regard to exposure to passive smoke, environmental contamination may cause
538 misinterpretations and false-positive test results [75]. Contamination is mainly due to cannabis
539 smoke, to direct contact with contaminated surfaces, without ruling out the possibility of an
540 exposure to urine aerosols present in contaminated public lavatories and public areas (Figure
541 1). To reduce this potential for contamination and prevent false-positive results, it is advisable to

542 perform extensive hair washing procedures before analyses, measure both THC and THC-
543 COOH, select appropriate cut-offs, and analyze the wash-off residue [25; 76; 77]. Because
544 marijuana smoke does not contain THC-COOH but THC, the detection of even trace
545 concentrations of THC-COOH might well indicate active use, whereas its absence does not
546 preclude cannabis consumption at all [4; 25; 77]. Some recent studies have also recommended
547 measuring THC-A in hair, in order to distinguish passive exposure from active cannabis use [4;
548 73; 78]. THC-A in hair originates exclusively from external contamination, mainly by direct
549 transfer after manipulation of cannabis plant material, or through smoke condensing on the hair
550 shaft. In cannabis smoke, only small amounts of THC-A are present resulting from incomplete
551 decarboxylation; this suggests a more important source of contamination than the deposition of
552 sidestream smoke. Consequently, THC-A is monitored as a biomarker of environmental
553 contamination.

554

555 *Interpretation*

556 Interpreting an analysis of the hair matrix is also quite complex. At least six mechanisms are
557 thought to be involved in the incorporation of cannabinoids into the hair's shaft and root. For the
558 hair shaft, cannabinoids may be incorporated from a) environmental exposure to cannabis
559 smoke, b) direct contact with a contaminated object or body part, c) exposure to sweat or d)
560 sebum, or e) diffusion from the skin. For the hair's root, cannabinoids could be incorporated
561 from the bloodstream during hair development [25; 30; 64]. Mechanisms a) and b) are related to
562 external contamination, whereas the other mechanisms require active biological processes. If
563 one supposes that cannabinoids are almost exclusively incorporated through the bloodstream, a
564 sequential analysis of hair segments would allow assessing past periods of drug consumption or
565 abstinence. However, it is currently assumed that the THC (like all the other plant cannabinoids
566 and CBN) measured in hair is almost exclusively the result of external contamination and not
567 from incorporation through the bloodstream. This has been evidenced by the distribution of THC
568 along the entire hair shaft after passive exposure to marijuana smoke, despite intensive hair
569 washing. Therefore, to retrospectively assess cannabis use, a segmental hair analysis is not
570 scientifically founded. Washing procedures are equally ineffective for removing other hair
571 contaminants, and similar observations have been noticed for THC metabolites. Because THC-
572 COOH concentrations decreased from the proximal to the distal segments of the hair shaft,
573 Auwärter et al. [4] suggested that metabolites are transferred to it via sebum by diffusion along
574 and inside the shaft. Moreover, results from segmental analyses evidenced barely any

575 correlation between self-reported past periods of consumption and changes in THC-COOH
576 levels in correspondingly aged hair segments [79].

577 Other important elements to consider in the interpretation of results are hair sampling sites and
578 the hair's condition. In their study involving the chronic marijuana smoke exposure of three
579 volunteers using a breathing apparatus to avoid smoke inhalation, Moosmann et al. [73]
580 observed that the degree of contamination depended on hair length and on the sampling site on
581 the skull. The posterior vertex (the back of the top) was the most contaminated area of the
582 head. This is also the sampling site that several scientific societies recommend for routine
583 forensic investigations. The study also noted that short hairs were less contaminated than long
584 hairs due to the more effective removal of hair sebum from the skin surface in daily washing;
585 hair sebum stores and transfers cannabinoids along the hair shaft [73]. Another explanation
586 could be that short hair is "younger" and its external cuticle is less porous and more impervious
587 than longer, older distal hair. The diffusion of external contamination into the cortex and medulla
588 of young hair is far less important. Likewise, physically or chemically damaged hairs are more
589 affected by external contamination than healthy hairs. They thus present a higher risk of testing
590 positive, even after a single exposure to cannabis smoke. The detection of damaged hair, as
591 suggested by Hill et al. [80], is thus an opportunity to avoid a cosmetic bias.

592 In summary, cannabinoid measurements in hair remain useful as a complementary matrix. A
593 lack of cannabinoid detection at the recommended cut-off levels suggests abstinence or very
594 occasional consumption. If THC is detected in hair, then it undoubtedly originates from
595 contamination, however, that does not mean that this contamination was not initiated by the
596 individual tested when smoking cannabis or preparing marijuana cigarettes. Contamination by
597 nearby smokers is also possible, especially in a heavily contaminated environment. To confirm
598 an external contamination, THC-A may be quantified. An extensive washing procedure should
599 also be performed before hair analysis and wash residues should be analyzed when necessary.

600

601 **Sweat and sebum**

602 As with OF and hair, sweat is a non-invasive means of collecting biological specimens. Based
603 on drug pharmacokinetics, sweat has been reported to be a suitable alternative matrix for
604 monitoring recent drug use or external contamination. Its fat properties also allows the transfer
605 of cannabinoids to the hair shaft [30].

606

607 *Analysis*

608 Sweat can be sampled by dedicated sweat patches (e.g., Pharmchek® absorption pads, Fort
609 Worth, Texas, USA); however, depending on the sampling site, sweat is generally mixed with
610 sebum, forming an emulsion [81]. This emulsion is sampled using special cotton swabs; sebum
611 is more easily collected using special lipid-sensitive tapes (e.g., Sebutape®, Cuderm Corp,
612 Dallas, USA or Sebufix®, C+K Electronic, Cologne, Germany). However, only the drug fraction
613 not bonded to proteins can diffuse from plasma to sweat through lipid membranes [81].
614 Nonetheless, the drug fraction excreted in sweat by passive diffusion is sufficient to be analyzed
615 using standard mass spectrometry methods. It remains that patch analysis requires sensitive
616 analytical methods (in the ng/patch range).

617

618 *Concentration ranges, contamination, and interpretation*

619 It appears that only THC can be measured in sweat; THC-COOH being never detected, or in
620 extremely low concentrations [82]. Because of its neutral properties, THC diffusion is suspected
621 to be slow [81]. Therefore, THC is monitored by using a patch sampling method from a specific
622 time point in order to detect recent cannabis use. The interpretation of results is complicated by
623 a potential re-absorption of THC by the skin, the adsorption of THC onto the patch-collection
624 device, and environmental contamination [30; 81]. No THC should be detected in sweat in
625 cases of passive exposure, as no THC was measured in recreational cannabis users, who
626 should have similar or higher exposure levels to cannabis than passive smokers [81]. Sebum,
627 however, could be a vector of THC-COOH by transferring it from bodily stores and fluids to hair
628 shafts [83].

629

630 **Analytical limitations**

631 In addition to a potential contamination, analytical issues may also be influential, and some
632 analytical methods produce artifacts. Typical examples are the hydrolysis of conjugates, the
633 conversion of THC-A into THC (under alkaline conditions or upon heating), the isomerization of
634 delta-9-THC into delta-8-THC (under acid conditions), or the possible conversion of CBD into
635 THC (under acid conditions). A further problem is that results are not always reported as levels
636 of free cannabinoids or as total cannabinoids (the sum of free and conjugated molecules), nor
637 are levels normalized to the creatinine concentration for urine samples. All these issues
638 complicate the interpretation of results and make comparisons impossible.

639

640 **Conclusion**

641 From the studies identified on passive exposure to cannabis of non-user subjects in controlled
642 conditions, specific biomarkers of passive cannabis exposure were identified in urine, blood,
643 oral fluid, hair, and sebum. It results that urine is an appropriate matrix to monitor passive
644 exposure, especially after normalization to creatinine levels. Important concentrations of THC-
645 COOH can be measured; however, concentrations exceeding the usual thresholds of positivity
646 require very extreme environmental conditions that cannot be ignored. Likewise, low blood
647 concentrations of THC and THC-COOH could be determined for a few hours following acute
648 exposure to heavy cannabis smoke. Measuring THC-COOH in blood is also a good alternative
649 for appraising passive exposure as it is detectable for a much longer time than THC and it
650 accumulates to high levels during chronic use. THC is detected in oral fluid after active
651 consumption or passive exposure. However, THC-COOH which is found only after voluntary
652 consumption can be considered as a reliable marker of active use. If the skin and the sebum are
653 easily contaminated by cannabis smoke, the skin layer limits the passage of cannabinoids into
654 the bloodstream. However, cannabinoids can be incorporated from sebum into the hair shaft by
655 diffusion. The presence of THC and THC-A in hair indicates that the subjects live or work in an
656 environment contaminated with cannabis. The detection of THC-COOH argues for regular
657 active use of cannabis. In contrast, a long period of abstinence can be strongly suspected if no
658 cannabinoids are detected in the hair shaft.

659 From a forensic outlook, in order to demonstrate conclusively that the cannabinoids measured
660 from different parts of the body are the result of active consumption, the expert should be able
661 to positively exclude different sources of potential contamination, such as:

- 662 • Self and cross-contamination from cannabis users: heavily contaminated hands and
663 fingers, contaminated surfaces or cannabis smoke can contaminate a non-smoker's
664 body as a result of poor personal hygiene and their environment;
- 665 • Extreme exposure to cannabis smoke: this may result in subjective and pharmacological
666 effects on physiology, behavior, cognitive capabilities, and psychomotor performances,
667 and these effects may sometimes be similar to those experienced by active smokers,
668 especially when the potency of cannabis is high;

669 • Secondhand smoke contamination: this should also be considered, especially in cases
670 of extreme exposure conditions. Thirdhand and secondhand contaminations are usually
671 difficult to discern and may be combined and cumulated.

672

673 As a concluding remark, the experts should clearly inform persons who have to demonstrate
674 prolonged abstinence from cannabis to avoid heavily smoky and unventilated areas. Moreover,
675 such persons must not handle or come into contact with objects and surfaces containing or
676 contaminated with cannabis material.

677

678 **Funding**

679 This work was supported by an internal grant from the University Department of Community
680 Medicine and Health (DUMSC) of the University Hospital (CHUV) of Lausanne (Switzerland).

681

682 **Conflict of interest**

683 All authors declare no conflict of interest.

684

685 **Research involving Human Participants and/or Animals**

686 This article does not contain any studies with human participants or animals performed by any
687 of the authors.

688

689 **Informed consent**

690 As this review does not contain any studies with human participants performed by any of the
691 authors, no informed consent was needed.

692

693

694 **Fig 1. Creative Commons License Deed**

695 Figure 1 is adapted from a figure in the Moosmann et al. [84] article entitled “Finding
696 cannabinoids in hair does not prove cannabis consumption”. The original version is licensed
697 under a Creative Commons Attribution 4.0 International License, a copy of which can be found
698 at <http://creativecommons.org/licenses/by/4.0/>. The figure was modified as follows, after
699 discussion with the original authors. An additional arrow indicates possible contamination of the
700 hair by urinary THC-COOH. The transfer of THC is described differently, with references to
701 secondhand and thirdhand smoke, and to mainstream and sidestream smoke. Secondhand
702 cannabis smoke is a mixture of the smoke from a smoldering marijuana cigarette (sidestream
703 smoke) and the smoke exhaled by a smoker (mainstream smoke). The cannabis smoke
704 condensate left on a variety of indoor surfaces, which is also a potential source of environmental
705 contamination, is known as thirdhand smoke.

706

References

- [1]. Office on Smoking and Health (US) (2006) The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK44324/>
- [2]. Martyny JW, Arbuckle SL, McCammon Jr CS, Erb N, Van Dyke M (2008) Methamphetamine contamination on environmental surfaces caused by simulated smoking of methamphetamine. *Journal of Chemical Health and Safety* 15: 25-31
- [3]. Winickoff JP, Friebely J, Tanski SE, Sherrod C, Matt GE, Hovell MF, McMillen RC (2009) Beliefs about the health effects of "thirdhand" smoke and home smoking bans. *Pediatrics* 123: e74-79. doi:10.1542/peds.2008-2184
- [4]. Auwarter V, Wohlfarth A, Traber J, Thieme D, Weinmann W (2010) Hair analysis for Delta9-tetrahydrocannabinolic acid A--new insights into the mechanism of drug incorporation of cannabinoids into hair. *Forensic Science International* 196: 10-13. doi:10.1016/j.forsciint.2009.12.023
- [5]. Cone EJ, Johnson RE (1986) Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. *Clinical pharmacology and therapeutics* 40: 247-256
- [6]. Cone EJ, Johnson RE, Darwin WD, Yousefnejad D, Mell LD, Paul BD, Mitchell J (1987) Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. *Journal of Analytical Toxicology* 11: 89-96
- [7]. Cone EJ, Roache JD, Johnson RE (1987) Effects of passive exposure to marijuana smoke. *NIDA Research Monograph Series* 76: 150-156
- [8]. Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R (2014) Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. *Journal of Analytical Toxicology* 39: 1-12. doi:10.1093/jat/bku116
- [9]. Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R (2015) Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects. *Journal of Analytical Toxicology*. doi:10.1093/jat/bkv070
- [10]. Herrmann ES, Cone EJ, Mitchell JM, Bigelow GE, LoDico C, Flegel R, Vandrey R (2015) Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. *Drug and alcohol dependence* 151: 194-202. doi:10.1016/j.drugalcdep.2015.03.019
- [11]. Law B, Mason PA, Moffat AC, King LJ, Marks V (1984) Passive inhalation of cannabis smoke. *The Journal of pharmacy and pharmacology* 36: 578-581
- [12]. Magerl H, Wiegand C, Schulz E (1987) [Cannabinoid intake by passive smoking]. *Archiv fur Kriminologie* 179: 31-37
- [13]. Mason AP, Perez-Reyes M, McBay AJ, Foltz RL (1983) Cannabinoids in plasma after passive inhalation of marijuana smoke. *JAMA : the journal of the American Medical Association* 249: 475-476
- [14]. Moore C, Coulter C, Uges D, Tuyay J, van der Linde S, van Leeuwen A, Garnier M, Orbita Jr J (2011) Cannabinoids in oral fluid following passive exposure to marijuana

- smoke. *Forensic Science International* 212: 227-230. doi:http://dx.doi.org/10.1016/j.forsciint.2011.06.019
- [15]. Morland J, Bugge A, Skuterud B, Steen A, Wethe GH, Kjeldsen T (1985) Cannabinoids in blood and urine after passive inhalation of Cannabis smoke. *Journal of forensic sciences* 30: 997-1002
- [16]. Mulé SJ, Lomax P, Gross SJ (1988) Active and Realistic Passive Marijuana Exposure Tested by Three Immunoassays and GCIMS in Urine. *Journal of Analytical Toxicology* 12: 113-116. doi:10.1093/jat/12.3.113
- [17]. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J, Robb J, Cone EJ (2001) Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. *Journal of Analytical Toxicology* 25: 289-303
- [18]. Niedbala RS, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ (2004) Passive Cannabis Smoke Exposure and Oral Fluid Testing. *Journal of Analytical Toxicology* 28: 546-552. doi:10.1093/jat/28.7.546
- [19]. Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, Waga J, Kurtz L, Bronsgeest M, Cone EJ (2005) Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. *Journal of Analytical Toxicology* 29: 607-615
- [20]. Palmeri A, Chessa C, Lopez A (1995) Passive smoking of hashish. Experimental contribution. *Zacchia* 68: 337-350
- [21]. Perez-Reyes M, Di Guiseppi S, Mason AP, Davis KH (1983) Passive inhalation of marihuana smoke and urinary excretion of cannabinoids. *Clinical pharmacology and therapeutics* 34: 36-41
- [22]. Rohrich J, Schimmel I, Zornlein S, Becker J, Drobnik S, Kaufmann T, Kuntz V, Urban R (2010) Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. *Journal of Analytical Toxicology* 34: 196-203
- [23]. Schimmel I, Drobnik S, Rohrich J, Becker J, Zornlein S, Urban R (2010) Passive cannabis exposure under realistic circumstances: A study in a coffee shop. *Blutalkohol* 47: 269-274
- [24]. Taura F, Sirikantaramas S, Shoyama Y, Shoyama Y, Morimoto S (2007) Phytocannabinoids in Cannabis sativa: Recent Studies on Biosynthetic Enzymes. *Chemistry & Biodiversity* 4: 1649-1663. doi:10.1002/cbdv.200790145
- [25]. Musshoff F, Madea B (2006) Review of Biologic Matrices (Urine, Blood, Hair) as Indicators of Recent or Ongoing Cannabis Use. *Therapeutic Drug Monitoring* 28: 155-163 110.1097/1001.ftd.0000197091.0000107807.0000197022
- [26]. Jung J, Meyer MR, Maurer HH, Neusüß C, Weinmann W, Auwärter V (2009) Studies on the metabolism of the Δ^9 -tetrahydrocannabinol precursor Δ^9 -tetrahydrocannabinolic acid A (Δ^9 -THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. *Journal of Mass Spectrometry* 44: 1423-1433. doi:10.1002/jms.1624
- [27]. Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004) Human skin permeation of Δ^8 -tetrahydrocannabinol, cannabidiol and cannabinol. *Journal of Pharmacy and Pharmacology* 56: 291-297. doi:10.1211/0022357022791

- [28]. Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in Man. In: Brande MC SS (ed), *The Pharmacology of Marijuana*. Raven Press, New York, pp 93-116
- [29]. Goulle JP, Sausseureau E, Lacroix C (2008) [Delta-9-tetrahydrocannabinol pharmacokinetics]. *Annales Pharmaceutiques Françaises* 66: 232-244. doi:10.1016/j.pharma.2008.07.006
- [30]. Huestis MA (2007) Human cannabinoid pharmacokinetics. *Chemistry & Biodiversity* 4: 1770-1804. doi:10.1002/cbdv.200790152
- [31]. Moffat AC (1986) Monitoring urine for inhaled cannabinoids. *Archives of Toxicology* 59: 103-110
- [32]. Perez-Reyes M (1990) Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Research Monograph 99, Rockville, MD
- [33]. Truitt EB, Jr. (1971) Biological disposition of tetrahydrocannabinols. *Pharmacol Rev* 23: 273-278
- [34]. ElSohly MA, Slade D (2005) Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sciences* 78: 539-548. doi:http://dx.doi.org/10.1016/j.lfs.2005.09.011
- [35]. Council NR (1982) *Marijuana and Health*. The National Academies Press, Washington, DC
- [36]. Balducci C, Nervegna G, Cecinato A (2009) Evaluation of principal cannabinoids in airborne particulates. *Analitica Chimica Acta* 641: 89-94. doi:10.1016/j.aca.2009.03.037
- [37]. Viana M, Postigo C, Balducci C, Cecinato A, López de Alda MJ, Barceló D, Artíñano B, López-Mahía P, Alastuey A, Querol X (2012) Psychoactive substances in airborne particles in the urban environment. In: Barcelo D (ed), *Emerging Organic Contaminants and Human Health. The Handbook of Environmental Chemistry*, vol 20. Springer-Verlag Berlin Heidelberg, pp 435-460. doi:10.1007/978-3-642-28132-7
- [38]. Falck R (1983) Passive inhalation of marijuana smoke. *JAMA : the journal of the American Medical Association* 250: 898
- [39]. Busuttill A, Obafunwa JO, Bulgin S (1996) Passive inhalation of cannabis smoke: a novel defence strategy? *Journal of clinical forensic medicine* 3: 99-104
- [40]. Giroud C, de Cesare M, Berthet A, Varlet V, Concha-Lozano N, Favrat B (2015) E-Cigarettes: A Review of New Trends in Cannabis Use. *International Journal of Environmental Research and Public Health* 12: 9988-10008. doi:10.3390/ijerph120809988
- [41]. Hayden JW (1991) Passive inhalation of marijuana smoke: a critical review. *Journal of Substance Abuse* 3: 85-90
- [42]. EMCDDA (2008) *A cannabis reader: global issues and local experiences*. vol 1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal
- [43]. Barr DB, Thomas K, Curwin B, Landsittel D, Raymer J, Lu C, Donnelly KC, Acquavella J (2006) Biomonitoring of Exposure in Farmworker Studies. *Environmental Health Perspectives* 114: 936-942. doi:10.1289/ehp.8527
- [44]. Scheidweiler KB, Desrosiers NA, Huestis MA (2012) Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem

- mass spectrometry. *Clinica Chimica Acta* 413: 1839-1847. doi:http://dx.doi.org/10.1016/j.cca.2012.06.034
- [45]. Bell R, Taylor EH, Ackerman B, Pappas AA (1989) Interpretation of urine quantitative 11-nor-delta-9 tetrahydrocannabinol-9-carboxylic acid to determine abstinence from marijuana smoking. *Journal of toxicology Clinical toxicology* 27: 109-115
- [46]. Lafolie P, Beck O, Blennow G, Boreus L, Borg S, Elwin CE, Karlsson L, Odelius G, Hjemdahl P (1991) Importance of creatinine analyses of urine when screening for abused drugs. *Clinical chemistry* 37: 1927-1931
- [47]. Smith ML, Barnes AJ, Huestis MA (2009) Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. *Journal of Analytical Toxicology* 33: 185-189
- [48]. Schwilke EW, Gullberg RG, Darwin WD, Chiang CN, Cadet JL, Gorelick DA, Pope HG, Huestis MA (2011) Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. *Addiction* 106: 499-506. doi:10.1111/j.1360-0443.2010.03228.x
- [49]. Westin AA, Slordal L (2009) [Passive inhalation of cannabis smoke--is it detectable?]. *Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke* 129: 109-113. doi:10.4045/tidsskr.09.33889
- [50]. Schroeder JL, Marinetti LJ, Smith RK, Brewer WE, Clelland BL, Morgan SL (2008) The analysis of delta9-tetrahydrocannabinol and metabolite in whole blood and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in urine using disposable pipette extraction with confirmation and quantification by gas chromatography-mass spectrometry. *J Anal Toxicol* 32: 659-666
- [51]. Toennes SW, Rohrich J, Wunder C (2010) [Interpretation of blood analysis data found after passive exposure to cannabis]. *Archiv fur Kriminologie* 225: 90-98
- [52]. Giroud C, Menetrey A, Augsburger M, Buclin T, Sanchez-Mazas P, Mangin P (2001) Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. *Forensic Science International* 123: 159-164
- [53]. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *British journal of pharmacology* 153: 199-215. doi:10.1038/sj.bjp.0707442
- [54]. Mason AP, Perez-Reyes M, McBay AJ, Foltz RL (1983) Cannabinoid concentrations in plasma after passive inhalation of marijuana smoke. *Journal of Analytical Toxicology* 7: 172-174
- [55]. Fabritius M, Augsburger M, Chtioui H, Favrat B, Giroud C (2014) Fitness to drive and cannabis: validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers. *Forensic Science International* 242: 1-8. doi:10.1016/j.forsciint.2014.05.014
- [56]. Fabritius M, Favrat B, Chtioui H et al. (2014) THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers? *Drug testing and analysis* 6: 155-163. doi:10.1002/dta.1581

- [57]. Lee D, Huestis MA (2014) Current knowledge on cannabinoids in oral fluid. *Drug testing and analysis* 6: 88-111. doi:10.1002/dta.1514
- [58]. Moore C (2012) Response to "Is THCCOOH a useful determinant for passive inhalation in oral fluid THC testing?". *Journal of Analytical Toxicology* 36: 358. doi:10.1093/jat/bks035
- [59]. Desrosiers NA, Scheidweiler KB, Huestis MA (2015) Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry. *Drug testing and analysis* 7: 684-694. doi:10.1002/dta.1753
- [60]. Scheidweiler KB, Himes SK, Chen X, Liu HF, Huestis MA (2013) 11-NOR-9-carboxy-delta9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry. *Therapeutic Drug Monitoring* 35 (5): 687
- [61]. Fabritius M, Staub C, Mangin P, Giroud C (2013) Analysis of cannabinoids in oral fluid by liquid chromatography-tandem mass spectrometry. *Forensic Toxicol* 31: 151-163. doi:10.1007/s11419-012-0168-z
- [62]. Moore C, Rana S, Coulter C, Day D, Vincent M, Soares J (2007) Detection of Conjugated 11-nor- Δ 9-Tetrahydrocannabinol-9-carboxylic Acid in Oral Fluid. *Journal of Analytical Toxicology* 31: 187-194. doi:10.1093/jat/31.4.187
- [63]. He X, Kozak M, Nimkar S (2012) Ultra-Sensitive Measurements of 11-Nor- Δ 9-Tetrahydrocannabinol-9-Carboxylic Acid in Oral Fluid by Microflow Liquid Chromatography-Tandem Mass Spectrometry Using a Benchtop Quadrupole/Orbitrap Mass Spectrometer. *Analytical Chemistry* 84: 7643-7647. doi:10.1021/ac3019476
- [64]. Goulle JP, Lacroix C (2006) [Which biological matrix for cannabis testing?]. *Annales Pharmaceutiques Françaises* 64: 181-191
- [65]. Milman G, Barnes AJ, Lowe RH, Huestis MA (2010) Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. *Journal of Chromatography A* 1217: 1513-1521
- [66]. Fabritius M, Chtioui H, Battistella G, Annoni J-M, Dao K, Favrat B, Fornari E, Lauer E, Maeder P, Giroud C (2013) Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. *Anal Bioanal Chem* 405: 9791-9803. doi:10.1007/s00216-013-7412-1
- [67]. Anizan S, Milman G, Desrosiers N, Barnes A, Gorelick D, Huestis M (2013) Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. *Anal Bioanal Chem* 405: 8451-8461. doi:10.1007/s00216-013-7291-5
- [68]. Cilio MR, Thiele EA, Devinsky O (2014) The case for assessing cannabidiol in epilepsy. *Epilepsia* 55: 787-790. doi:10.1111/epi.12635
- [69]. Lee D, Schwoppe DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA (2012) Cannabinoid Disposition in Oral Fluid after Controlled Smoked Cannabis. *Clinical chemistry* 58: 748-756. doi:10.1373/clinchem.2011.177881
- [70]. Milman G, Schwoppe DM, Gorelick DA, Huestis MA (2012) Cannabinoids and Metabolites in Expectorated Oral Fluid Following Controlled Smoked Cannabis. *Clinica Chimica Acta; International Journal of Clinical Chemistry* 413: 765-770. doi:10.1016/j.cca.2012.01.011

- [71]. Duvivier WF, van Beek TA, Pennings EJM, Nielen MWF (2014) Rapid analysis of Δ -9-tetrahydrocannabinol in hair using direct analysis in real time ambient ionization orbitrap mass spectrometry. *Rapid Communications in Mass Spectrometry* 28: 682-690. doi:10.1002/rcm.6831
- [72]. Nakahara Y, Takahashi K, Kikura R (1995) Hair analysis for drugs of abuse. X. Effect of physicochemical properties of drugs on the incorporation rates into hair. *Biological and Pharmaceutical Bulletin* 18: 1223-1227
- [73]. Moosmann B, Roth N, Auwarter V (2014) Hair analysis for THCA-A, THC and CBN after passive in vivo exposure to marijuana smoke. *Drug testing and analysis* 6: 119-125. doi:10.1002/dta.1474
- [74]. ElSohly MA, deWit H, Wachtel SR, Feng S, Murphy TP (2001) Δ -9-Tetrahydrocannabinol as a Marker for the Ingestion of Marijuana versus Marinol®: Results of a Clinical Study. *Journal of Analytical Toxicology* 25: 565-571. doi:10.1093/jat/25.7.565
- [75]. Thorspecken J, Skopp G, Potsch L (2004) In vitro contamination of hair by marijuana smoke. *Clinical chemistry* 50: 596-602
- [76]. Tsanaclis L, Nutt J, Bagley K, Bevan S, Wicks J (2014) Differentiation between consumption and external contamination when testing for cocaine and cannabis in hair samples. *Drug testing and analysis* 6: 37-41. doi:10.1002/dta.1623
- [77]. Tsanaclis L, Wicks JFC (2008) Differentiation between drug use and environmental contamination when testing for drugs in hair. *Forensic Science International* 176: 19-22. doi:http://dx.doi.org/10.1016/j.forsciint.2007.08.009
- [78]. Moosmann B, Roth N, Auwarter V (2015) Hair analysis for Delta -tetrahydrocannabinolic acid A (THCA-A) and Delta -tetrahydrocannabinol (THC) after handling cannabis plant material. *Drug testing and analysis*. doi:10.1002/dta.1830
- [79]. Han E, Chung H, Song JM (2012) Segmental Hair Analysis for 11-Nor- Δ -9-Tetrahydrocannabinol-9-Carboxylic Acid and the Patterns of Cannabis Use. *Journal of Analytical Toxicology* 36: 195-200. doi:10.1093/jat/bks010
- [80]. Hill V, Loni E, Cairns T, Sommer J, Schaffer M (2014) Identification and analysis of damaged or porous hair. *Drug testing and analysis* 6 Suppl 1: 42-54. doi:10.1002/dta.1652
- [81]. de la Torre R, Pichini S (2004) Usefulness of Sweat Testing for the Detection of Cannabis Smoke. *Clinical chemistry* 50: 1961-1962. doi:10.1373/clinchem.2004.040758
- [82]. Staub C (1999) Chromatographic procedures for determination of cannabinoids in biological samples, with special attention to blood and alternative matrices like hair, saliva, sweat and meconium. *Journal of Chromatography B: Biomedical Sciences and Applications* 733: 119-126. doi:http://dx.doi.org/10.1016/S0378-4347(99)00249-2
- [83]. Moosmann B, Auwarter V (2015) Δ -9-Tetrahydrocannabinol (THC) and 11-nor-9-carboxy-THC (THC-COOH) findings in hair samples after controlled oral intake of dronabinol. Paper presented at the XIX. GTFCh-Symposium, Baden, Germany, April 16-18, 2015
- [84]. Moosmann B, Roth N, Auwarter V (2015) Finding cannabinoids in hair does not prove cannabis consumption. *Scientific Reports* 5: 14906. doi:10.1038/srep14906

Table 1 Cut-offs proposed by different scholarly societies according to biological matrices and analytes

Society	Biological matrix	Initial test analyte (immunoassay)	Initial test cut-off concentration	Confirmatory test analyte	Confirmatory test cut-off concentration
SAMHSA 2008 ^{a,b}	urine	Marijuana metabolites	50 ng/mL	THC-COOH total	15 ng/mL
GTFCh ^c	urine			THC-COOH total	10 ng/mL
EWDTs 2015 ^d	urine	Marijuana metabolites	50 ng/mL	THC-COOH	15 ng/mL
GTFCh ^c	serum/plasma			THC free	1 ng/mL
GTFCh ^c	serum/plasma			THC-COOH free	10 ng/mL
SFTA ^e	whole blood			THC	0.5 ng/mL
SFTA ^e	whole blood			THC-COOH	2.0 ng/mL
GTFCh ^c	hair			THC	0.02 ng/mg
SoHT ^f	hair	THC	0.1 ng/mg	THC	0.1 ng/mg
SoHT ^f	hair			THC-COOH	0.2 pg/mg
EWDTs 2015 ^d	hair	THC	0.05 ng/mg	THC	0.05 ng/mg
EWDTs 2015 ^d	hair			THC-COOH	0.2 pg/mg
SAMHSA 2004 ^g	hair	Marijuana metabolites	1 pg/mg	THC-COOH	0.05 pg/mg
SAMHSA 2004 ^g	oral fluid/saliva	THC	4 ng/mL	THC	2 ng/mL
SAMHSA 2015 (proposal) ^h	oral fluid/saliva	THC	2-3 ng/mL	THC	1 ng/mL
SAMHSA 2015 (proposal) ^h	oral fluid/saliva			THC-COOH	50 pg/mL
EWDTs 2015 ^d	oral fluid/saliva	THC	10 ng/mL	THC	2 ng/mL
SAMHSA 2004 ^g	sweat patch	Marijuana metabolites	4 ng/patch	THC	1 ng/patch

^a Substance Abuse and Mental Health Services Administration (SAMHSA) (2008) Mandatory guidelines for Federal workplace drug testing programs. Federal Register, 73, No. 228. pp. 71,858–71,907. Rockville, MD: Substance Abuse and Mental Health Services Administration. Available at: <https://www.gpo.gov/fdsys/pkg/FR-2008-11-25/pdf/E8-26726.pdf>. Accessed December 18, 2015.

^b Substance Abuse and Mental Health Services Administration (SAMHSA) (2015) Notice of proposed mandatory guidelines for Federal workplace drug testing programs – Urine. Federal Register, 80, No. 94. pp. 28,101–28,151. Rockville, MD: Substance Abuse and Mental Health Services Administration. Available at: <https://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-11524.pdf>. Accessed December 18, 2015.

^c GTFCh: Gesellschaft für Toxikologische und Forensische Chemie. Anhang A zur Richtlinie zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen. Qualitätsanforderungen an die Bestimmung spezieller Analyten aus biologischen Matrices mit Tabellenanhang (aktuelle Vorgaben zu Bestimmungsgrenzen). 01.06.2009. Toxichem Krimtech (2009) 76 (3): 177-184.

^d EWDTs: European Laboratory Guidelines for Legally Defensible Workplace Drug Testing (2015). Available at: <http://www.ewdts.org/ewdts-guidelines.html>. Accessed December 18, 2015.

^e SFTA: Société Française de Toxicologie Analytique. Consensus Cannabis, 2013, June 14th. Available at: http://www.sfta.org/img/uploads/2015/07/Consensus_cannabis_2013.pdf. Accessed December 18, 2015.

^f SoHT: Society of Hair Testing. Consensus on hair testing, 2003, October 7th. Available at: http://www.soht.org/images/pdf/Consensus_on_Hair_Analysis.pdf. Accessed December 18, 2015.

^g Substance Abuse and Mental Health Services Administration (SAMHSA) (2004) Mandatory guidelines and proposed revisions to mandatory guidelines for Federal workplace drug testing programs. Federal Register, 69, No. 71. pp. 19,675–

19,732. Rockville, MD: Substance Abuse and Mental Health Services Administration. Available at: <https://www.gpo.gov/fdsys/pkg/FR-2004-04-13/html/04-7984.htm>. Accessed December 18, 2015.

^h Substance Abuse and Mental Health Services Administration (SAMHSA) (2015) Notice of proposed mandatory guidelines for Federal workplace drug testing programs – Oral fluid. Federal Register, 80, No. 94. pp. 28,054–28,101.

Rockville, MD: Substance

Abuse and Mental Health Services Administration. Available at: <https://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-11523.pdf>

Table 2 Summary of the analytical methods used, the cut-offs, and the maximum cannabinoid body fluid concentrations reported in studies on the passive exposure to cannabis

Reference	Matrix	Analytes	Analytical method ^a	LOD of analytical method (ng/mL)	Cut-off (ng/mL)	Exposure time (min)	THC dose (mg)	C _{max} (ng/mL) (time after exposure) ^b
[21] Study I	Urine	Cannabinoids	EMIT	n.a.	20	60	46	< cut-off
Study II	Urine	Cannabinoids	EMIT	n.a.	20		52	< cut-off
Study III	Urine	Cannabinoids	EMIT	n.a.	20		105	< cut-off
[13]	Plasma	THC	RIA	n.a.	3	60	105	2.2 (5 min)
		THC	GC/MS	0.2	n.a.			4 (5 min)
		11-OH-THC	GC/MS	0.5	n.a.			Negative
		THC-COOH	GC/MS	0.1	n.a.			< 0.1
[11]	Urine	THC-COOH + its ester glucuronide	RIA	0.32 ± 0.23 (mean ± SD)	2	180	103	4.7 (90 min)
	Plasma	THC-COOH + its ester glucuronide	RIA	1.8 ± 2.5 (mean ± SD)	2			0
[15] Study I	Urine	Cannabinoids	EMIT	n.a.	20	30	90	Negative
		Cannabinoids	RIA	n.a.	13			NA
	Blood	Cannabinoids	RIA	n.a.	13			< cut-off
		THC	GC/MS	0.5	0.5			1.3 – 6.3 (immediately)
[15] Study II	Urine	Cannabinoids	EMIT	n.a.	20	30	90	< cut-off
		Cannabinoids	RIA	n.a.	13			21 (immediately)
	Blood	Cannabinoids	RIA	n.a.	13			20 (immediately)
		THC	GC/MS	0.5	0.5			1.3 – 6.3 (immediately)
[5-7]	Urine	Cannabinoids	EMIT	n.a.	20	60 (6 consecutive days)	393.4 (average weight of cigarettes: 877±20 mg)	Positive urines after 1 st exposure session for 6 subjects (n = 16 cigs) ≈75 days 2–6 (n = 16 cigs)
		Cannabinoids	RIA	5	10			≈14.1 days 2–6 (n = 4 cigs)
		THC-COOH	GC/MS	2	5			30 at day 4 (n = 16 cigs)
	Plasma	THC	RIA	1.5	2.5			almost 0 (n = 4 cigs) 7.3 at day8 (n = 16 cigs) 2.5 at day6 (n = 4 cigs)

Reference	Matrix	Analytes	Analytical method ^a	LOD of analytical method (ng/mL)	Cut-off (ng/mL)	Exposure time (min)	THC dose (mg)	C _{max} (ng/mL) (time after exposure) ^b	
[16]	Urine	Cannabinoids	RIA	n.a.	12	60	108	< 6	
[20] Study I	Urine	THC	EMIT	n.a.	20	60	45	8.5 (120 min)	
Study II	Urine	THC	ADx	n.a.	25	30	30	5.7 (44 h)	
		THC	EMIT	n.a.	20			9.6 (7h)	
[17]	Urine	THC	ADx	n.a.	25	240	n.a.	21.3 (7 h)	
		THC-COOH	EIA	3	50			3.2 (24 h)	
	THC-COOH	GC/MS/MS	5	15	Negative				
	THC	EIA	0.5	1	Positive (60 min)				
[18]	Urine	THC	GC/MS/MS	0.2l	0.5	240	n.a.	Negative	
		THC-COOH	EIA	n.a.	50			Negative	
	THC-COOH	GC/MS/MS	1	1	0.9 (5 min)				
	Oral fluid	THC	EIA	n.a.	3			Positive (20 min after start of exposure)	
[19] Study I	Urine	THC	GC/MS/MS	0.3	0.75	60	158	13.4 (20 min after start of exposure)	
		THC-COOH	EIA	n.a.	50			Negative	
	THC-COOH	GC/MS/MS	1	1	8.4 (6h)				
	Oral fluid	THC	EIA	n.a.	3			Positive (15 min)	
	Study II	Urine	THC	GC/MS/MS	0.3			0.75	5.3 (immediately)
			THC-COOH	EIA	n.a.			50	Negative
[22]	Urine	THC-COOH	GC/MS/MS	1	1	180	n.a.	8.9 (6h)	
		THC	EIA	n.a.	3			Negative	
	THC	GC/MS/MS	0.3	0.75	1 (90 min)				
	Hydrolyzed urine	THC-COOH	ELISA	n.a.	0.6			0.8 (30 min)	
[23]	Urine	Cannabinoids	EIA	n.a	25	180	8 g of hashish and marijuana were burnt	9.8 (3h)	
		THC-COOH	GC/MS	1	8			3.6 (3h)	
	Hydrolyzed urine	THC-COOH	GC/MS	0.4	0.6			2.3 (11h)	
	Serum	Cannabinoids	ELISA	1	3			3.8 (11h)	
[23]	Urine	THC	GC/MS	0.1	0.5	180	8 g of hashish and marijuana were burnt	3 (30 min)	
		Cannabinoids	EIA	n.a	25			0.5 (1.5 h after the start of exposure)	
	Serum	Cannabinoids	EIA	n.a	3			Negative	
[23]	Urine	THC-COOH	GC/MS	1	8	180	8 g of hashish and marijuana were burnt	3.6 (3h)	
		THC	GC/MS	0.1	1			2/8 volunteers positive (30 min)	
		THC	GC/MS	0.1	1			Negative	

Reference	Matrix	Analytes	Analytical method ^a	LOD of analytical method (ng/mL)	Cut-off (ng/mL)	Exposure time (min)	THC dose (mg)	C _{max} (ng/mL) (time after exposure) ^b
[14] Location 1	Oral fluid	11-OH-THC	GC/MS	0.1	1	180	n.a.	Negative ≈ LOD (0.5-3 h) Positive over the 20 min to 3h exposure 4.3 (2h after the start of exposure) 0.7 (2h after the start of exposure)
		THC-COOH	GC/MS	1	8			
		THC	ELISA	2	4			
		THC	GC/MS	0.5	0.5			
		Cannabinol	GC/MS	0.5	0.5			
Location 2	Oral fluid	Cannabidiol	GC/MS	1	1	180	n.a.	Positive (immediately) 7.5 (immediately) 0.9 (immediately) Negative Negative
		THC-COOH	Two-dimensional GC-GC/MS	0.002	> 0.002			
		THC	ELISA	2	4			
		THC	GC/MS	0.5	0.5			
		Cannabinol	GC/MS	0.5	0.5			
[8; 9] Session I	Urine	Cannabidiol	Two-dimensional GC-GC/MS	0.002	> 0.002	60	5.3%	Negative 85.6 (4-6h) 22.4 (4-6h) 1.4 (15 min)
		THC	EMIT	n.a.	50			
		THC-COOH	EMIT	n.a.	20			
		THC-COOH	GC/MS	0.75	15			
		THC	LC/MS/MS	0.1	0.5			
[8; 9] Session I	Whole blood	THC-COOH (free)	LC/MS/MS	0.1	0.5	60	5.3%	1.2 (15 min) Negative Positive (15 min) 34 (15 min) Negative
		11-OH-THC	LC/MS/MS	0.1	0.5			
		Cannabinoids	ELISA	2	4			
		THC	LC/MS/MS	0.1	1			
		THC-COOH (total)	LC/MS/MS	0.02	0.02			
Session II	Urine	Cannabinoids	Two-dimensional GC-GC/MS	0.002	> 0.002	60	11.3%	Negative 140 (4h) 33.3 (4h) 3.1 (15 min)
		THC	EMIT	n.a.	50			
		THC-COOH	EMIT	n.a.	20			
		THC-COOH	GC/MS	0.75	15			
		THC	LC/MS/MS	0.1	0.5			
Session II	Whole blood	THC-COOH (free)	LC/MS/MS	0.1	0.5	60	11.3%	2.5 (15 min) Negative Positive (15 min)
		11-OH-THC	LC/MS/MS	0.1	0.5			
		Cannabinoids	ELISA	2	4			
		THC	LC/MS/MS	0.1	1			
		THC-COOH (total)	LC/MS/MS	0.02	0.02			
Session II	Oral Fluid	Cannabinoids	Two-dimensional GC-GC/MS	0.002	> 0.002	60	11.3%	2.5 (15 min) Negative Positive (15 min)
		THC	EMIT	n.a.	50			
		THC-COOH	EMIT	n.a.	20			
		THC-COOH	GC/MS	0.75	15			
		THC	LC/MS/MS	0.1	0.5			

Reference	Matrix	Analytes	Analytical method ^a	LOD of analytical method (ng/mL)	Cut-off (ng/mL)	Exposure time (min)	THC dose (mg)	C _{max} (ng/mL) (time after exposure) ^b
Session III	Urine	THC	LC/MS/MS	0.1	1	60	11.3%	81.5 (15 min)
		THC-COOH (total)	LC/MS/MS	0.02	0.02			Negative
		Cannabinoids	EMIT	n.a.	50			Negative
		THC	EMIT	n.a.	20			55.2 (4-6h)
		THC-COOH	GC/MS	0.75	15			8.61 (4h)
		THC	LC/MS/MS	0.1	0.5			0.5 (15 min)
	Whole blood	THC-COOH (free)	LC/MS/MS	0.1	0.5	0.2 (15 min)		
		11-OH-THC	LC/MS/MS	0.1	0.5	Negative		
		Oral Fluid	Cannabinoids	ELISA	2	4	Positive (15 min)	
			THC	LC/MS/MS	0.1	1	16.9 (15 min)	
			THC-COOH (total)	LC/MS/MS	0.02	0.02	Negative	
			THC-COOH	EMIT	n.a.	10	Negative	
[73]	Urine	THC-COOH	EMIT	n.a.	10	500 mg of marijuana containing 9.2% THC	Negative	
Hair	THC-A	LC/MS/MS	2.5 pg/mg	2.5 pg/mg	15-20 min (one joint) every weekday for 3 weeks		17.3 pg/mg (end of exposure period)	
	THC	LC/MS/MS	20 pg/mg	20 pg/mg	803 pg/mg (end of exposure period)			
	Cannabinol	LC/MS/MS	20 pg/mg	20 pg/mg	307 pg/mg (end of exposure period)			

EIA: Cannabinoids Intercept MICRO-PLATE Enzyme Immunoassay; ELISA: Enzyme linked immunosorbent assay; EMIT: Enzyme multiplied immunoassay technique; GC/MS: Gas chromatography–mass spectrometry; GC/MS/MS: Gas chromatography–tandem mass spectrometry; LC/MS/MS: liquid chromatography coupled with tandem mass spectrometry; n.a.: non available; RIA: Radioimmunoassay;

^a Analytical methods reported to be used in the referent study on passive exposure to cannabis.

^b The maximal concentration obtained in calculating a mean between the non-smoker values at a specific time.

1 **Figure captions**

2

3 **Fig. 1** Potential external cross-contamination from cannabis use and incorporation pathways of
4 cannabinoids into human hair. Incorporation of Δ 9-tetrahydrocannabinolic acid A (THCA-A), Δ 9-
5 tetrahydrocannabinol (THC), and its metabolite, 11-nor-9-carboxy-THC (THC-COOH), into
6 human hair can occur in the hair's root via the bloodstream, by diffusion from sweat or sebum
7 into the hair shaft, or by external contamination (e.g., contaminated fingers or sidestream
8 smoke). The main metabolic pathway for THC and the molecular structures of its analytes are
9 also given. Reprinted and adapted with the permission by "Nature Publishing Group" and
10 "Creative Commons", "Finding cannabinoids in hair does not prove cannabis consumption,
11 2015, p. 2, Figure 1" [84].

12

13 **Fig. 2** Bioavailability and elimination of cannabinoids in different matrices following passive
14 exposure to cannabis smoke. Cannabinoids in bold type denote markers considered suitable for
15 differentiating passive from active exposure. Reprinted and adapted with permission by
16 "Science Direct" and "Elsevier Science", "Mise en evidence des cannabinoïdes : quel milieu
17 biologique ? [Which biological matrix for cannabis testing?], 2006, p. 186, Figure 5" [64].

18

19 **Fig. 3** THC-COOH concentration time profiles in urine reported in several studies on passive
20 exposure to cannabis smoke. Profiles are adjusted for creatinine concentrations. Each study is
21 identified by a differently-shaped dot, with different colors denoting different sessions.

22





23 **Fig. 4** Concentration time profiles of a) THC in plasma or b) THC-COOH in serum and whole
24 blood reported in several studies on passive exposure to cannabis smoke. Each study is
25 identified by a differently-shaped dot, with different colors denoting different sessions.


26


27 **Fig. 5** THC concentration time profiles in oral fluid reported in several studies on passive
28 exposure to cannabis smoke. Each study is identified by a differently-shaped dot, with different
29 colors denoting different sessions.


30


31











Non-relevant articles by title:

Articles or studies on animals, relative to infertility, preconception, pregnancy, infants, children, teen-agers, nicotine dependence, effects of cannabis use, health effects, polymorphism, human milk.

Non-relevant articles by abstract:

No human biomonitoring sampling, quantification methods only, no passive volunteers or participants, opinion.

Non-relevant articles by full texts:

No data on passive exposure (human biological matrices), no placebo volunteers (only smokers), no relevant data.

Table 1 Summary of the analytical methods used and the cannabinoid body fluid concentrations reported in studies on the passive inhalation of cannabis

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
Perez-Reyes et al. (1983)								
Urine (Study I)	EMIT	20	Cannabinoids	All urines collected separately for 24 h after exposure	26 urine samples	24 h after exposure		Urinary drug levels were below the cut-off
Urine (Study II)	EMIT	20	Cannabinoids	All urines collected separately for 24 h after exposure	23 urine samples	24 h after exposure		One urine was above the cut-off at 6 h after exposure
Urine (Study III)	EMIT	20	Cannabinoids	All urines collected separately for 3 consecutive days	27 urine samples	72 h after exposure		One urine slightly above the cut-off at 5 h after 3 rd exposure day
Plasma (Study III)	RIA	NA	THC	Blood collected from one subject at different intervals for 1 h after exposure	11 blood samples	1 h after the 2 nd exposure day	1.9 ng/ml	2.2 ng/ml at 5 min after exposure
Mason et al. (1983)								
Plasma	RIA	3	THC		24 blood samples		1.9 ng/ml	2–2.2 ng/ml at 5 min after exposure
	GC/MS	NA	THC	Blood samples obtained at frequent intervals from beginning of exposure to 1 h after exposure	24 blood samples	1 h after exposure	3 ng/ml	4 ng/ml at 5 min after exposure
			11-OH-THC				NA	Not detected
			THC-COOH				0.5 ng/ml	< 0.5 ng/ml
Law et al. (1984)								
Urine	RIA	2	11-OH-THC- and its ester glucuronide	At 0, 1, 2, 3, 6 h	20 urine samples	6 h after start of exposure	4.2 ng/ml at 6 h after start of exposure	4.7 ng/ml at 4.5 h after start of exposure
Plasma	RIA	NA		At 0, 0.5, 1, 2 and 4 h	20 blood samples	4 h after start of exposure	NA	0 ng/ml
Morland et al. (1985)								
Urine (Study I) ^b	EMIT	20	Cannabinoids	Before exposure, 0 to 4h, 4 to 24 h, and days 2, 3, 4, and 5	11 urine samples	Day 5 morning	Negative	Negative
	RIA	13	Cannabinoids				NA	NA
Blood (Study I) ^b	RIA	13	Cannabinoids	Before exposure, immediately after exposure (0.5 h) and 2 h later (2.5 h)	6 blood samples	2.5 h after start of exposure	0 ng/ml	One sample was at the cut-off at 30 min.

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
	GC/MS	0.5	THC				0 ng/ml	1.2 ng/ml at 30 min after start of exposure
Urine (Study II) ^c	EMIT	20	Cannabinoids	Before exposure, 0 to 4h, 4 to 24h, and days 2, 3, 4, and 5	20 urine samples	Day 5 morning	Negative	One sample positive at 4–24 h
	RIA	13	Cannabinoids				< cut-off	22 ng/ml at Day 2 morning
Blood (Study II) ^c	RIA	13	Cannabinoids	Before exposure, immediately after exposure (0.5 h) and 2 h later (2.5 h)	9 blood samples	2.5 h after start of exposure	18 ng/ml	26 ng/ml at 30 min after start of exposure
	GC/MS	0.5	THC				0 ng/ml	5.2 ng/ml at 30 min after start of exposure
Cone and Johnson (1986); Cone et al. (1987a); Cone et al. (1987b)								
Urine	EMIT	20 and 75	Cannabinoids	<i>Ad libidum</i> + daily at 8:00, 16:00 and 24:00 to complete the collection period.	n = 882 (682 + 200)	14 days for 16-cig exposure study (n = 16 cigs); 10 days for 4-cig exposure study (n = 4 cigs)	< cut-off (n = 4 or 16 cigs)	Positive urines after 1 st exposure session for 6 subjects (n = 16 cigs) and 4/5 subjects over the 6-day exposure (n = 4 cigs)
	RIA	10	Cannabinoids				0 ng/ml (n = 4 or 16 cigs)	≈75 ng/ml days 2–6 (n = 16 cigs) ≈14.1 ng/ml days 2–6 (n = 4 cigs)
	GC/MS	5	THC-COOH				0 ng/ml (n = 4 or 16 cigs)	30 ng/ml at day 4 (n = 16 cigs) almost 0 ng/ml (n = 4 cigs)
Plasma (venous blood)	RIA	2.5	THC	30 min prior and 20–30 min following each exposure session with 16 cigs (only 1 subject donated blood samples during the 4-cig exposure study)	55 blood samples (n = 16 cigs) and 10 blood samples (n = 4 cigs)	10 days (n = 16 cigs) and 9 days (n = 4 cigs)	0 ng/ml (n = 4 or 16 cigs)	7.3 ng/ml at day8 (n = 16 cigs) 2.5 ng/ml at day6 (n = 4 cigs)
Mule et al. (1988)								
Urine	RIA	12	Cannabinoids	20–24 h after exposure	3	24 h	< 6 ng/ml	NA
Palmieri et al. (1995)								
Urine (Study I)	EMIT	20	THC	Before exposure, 2, 12, and 20 h and for next 6 mornings	27 urine samples	164 h after exposure	NA	8.5 ng/ml at 2 h
	ADx	25	THC	(44, 68, 92, 116, 140, and 164h)			0 ng/ml	5.7 ng/ml at 44 h

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
Urine (Study II)	EMIT	20	THC	Before exposure, 3, 7, and 16h and for next 4 mornings (40, 64, 88, and 112h)	21 urine samples	112 h after exposure	0 ng/ml	9.6 ng/ml at 7 h
	ADx	25	THC				0 ng/ml	21.3 ng/ml at 7 h
Niedbala et al. (2001)								
Oral fluid (OF)	EIA	1	THC	Prior to exposure and at 1, 2, 4, 8, 16, 24, 48, and 72 h after marijuana administration	18 OF samples		Negative	Positive at 1h
	GC/MS/MS	0.5	THC			72 h following start of exposure	0 ng/ml	0 ng/ml
Urine	EIA	50	THC-COOH	Prior to exposure and at 1, 2, 4, 8, 16, 24, 48, and 72 h after marijuana administration	18 urine samples		9.7 ng/ml ^d	3.2 ng/ml at 24 h ^d
	GC/MS	15	THC-COOH				0 ng/ml	0 ng/ml
Niedbala et al. (2004)								
Oral fluid (OF)	EIA	3	THC	Before exposure and at 20, 35, 50, 65, 95, 125, 155, 185, 215, and 245 min after start of exposure	44 OF samples	245 min	Negative	Positive at 20 min
	GC/MS/MS	0.75	THC				0 ng/ml	13.4 ng/ml at 20 min after start of exposure
Urine	EIA	50	THC-COOH	Before exposure and at 20 and 245 min after start of exposure.	12 urine samples	245 min	Negative	Negative
	GC/MS/MS	1	THC-COOH				0.9 ng/ml	0.9 ng/ml at 245 min after start of exposure
Niedbala et al. (2005)								
Oral fluid (OF) (Study I)	EIA	3	THC	Before exposure and at 0 (immediately at end of smoking), 15, 30, and 45 min (inside the van) and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 h (outside of the van)	184 OF samples	72 h	Negative	Positive at 0 and 15 min after exposure
	GC/MS/MS	0.75	THC				≈ 0 ng/ml	5.3 ng/ml immediately after exposure
Urine (Study I)	EIA (EMIT)	50	THC	Before exposure and at 1, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 h after start of exposure	48 urine samples	72 h	Negative	Negative
	GC/MS/MS	1	THC-COOH				1.2 ng/ml ^d	8.4 ng/ml at 6 h after exposure ^d
Oral fluid (OF) (Study II)	EIA	3	THC	Before exposure and at 0 (immediately at end of smoking), 15, 30, 45 min, 1,	184 OF samples	72 h	Negative	Negative
	GC/MS/MS	0.75	THC				0 ng/ml	1 ng/ml at 1.5 h after exposure

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
				1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 h (outside the van)				
Urine (Study II)	EIA (EMIT)	50	THC	Before exposure and at 1, 2, 4, 6, and 8 h.	24 urine samples	8 h	Negative	Negative
	GC/MS/MS	1	THC-COOH				7.3 ng/ml ^d	8.9 ng/ml at 6 h after exposure ^d
Rohrich et al. (2010)								
Serum	ELISA	3	Cannabinoids	Before exposure and at 1.5, 3.5, 6, and 14 h after start of exposure	25 blood samples	14 h	2 ng/ml	3 ng/ml at 3.5 h after start of exposure
	GC/MS	0.5	THC				0 ng/ml	0.5 ng/ml at 1.5 h after start of exposure
Urine	ELISA	0.6	THC-COOH	Before exposure and at 3.5, 6, 14, 36, 60, and 84 h after start of exposure.	40 urine samples	84 h	0.3 ng/ml	0.8 ng/ml at 3.5 h after start of exposure
	EIA	25	Cannabinoids				1.4 ng/ml ^d	9.8 ng/ml at 6 h after start of exposure ^d
	GC/MS	0.6	THC-COOH				0 ng/ml	2.3 ng/ml at 14 h after start of exposure
		1	THC-COOH (hydrolyzed urine)				0.4 ng/ml	3.8 ng/ml at 14 h after start of exposure
Schimmel et al. (2010)								
Blood (Serum)	EIA	3	Cannabinoids	Before exposure and at 1.5, 3.5, 6, and 14 h after start of exposure	16	14 h	Negative	Positive for 2 volunteers at 1.5 and 3.5 h
	GC/MS	1	THC				0 ng/ml	0 ng/ml
		1	11-OH-THC				0 ng/ml	0 ng/ml
		8	THC-COOH				<LOD	4 samples were > LOD (1 to 2 ng/ml at 3.5–6 h)
Urine	EIA	25	Cannabinoids	Before exposure and at 3.5, 6, 14, 36, 60 and 84 h after	24	84 h	Negative	Negative

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
	GC/MS	8	THC-COOH	start of exposure			0 ng/ml	3.6 ng/ml at 6h and 3.7 ng/ml at 14 h
Moore et al. (2011)								
Oral fluid (OF) (Location 1)	ELISA	4	THC	Before exposure, at 20, 40, 60, 120, and 180 min during passive exposure to marijuana (outside coffee shop), and between 12 and 22 h (average 14.6 h) after leaving the coffee shop	70 OF samples	180 min	> 4 ng/ml for 3 subjects	Positive over the 20 min to 3 h period
	GC/MS	0.5	THC			12–22 h	0.4 ng/ml	4.3 ng/ml at 2 h
		0.5	Cannabinol				0 ng/ml	0.7 ng/ml at 2 h
		1 (CBD)	Cannabidiol				0 ng/ml	0 ng/ml
	Two-dimensional GC-GC/MS	0.002	THC-COOH				0 ng/ml	0 ng/ml
Oral fluid (OF) (Location 2)	ELISA	4	THC	Before exposure, at 20, 40, 60, 120, and 180 min during passive exposure to marijuana (outside the coffee shop), and between 12 and 22 h (average 14.6 h) after leaving the coffee shop	70 OF samples	180 min	THC: > 4 ng/ml for 3 subjects	Positive at the 3 h period
	GC/MS	0.5	THC			12–22 h	0 ng/ml	7.5 ng/ml at 3 h
		0.5	Cannabinol				0 ng/ml	0.9 ng/ml at 3 h
		1 (CBD)	Cannabidiol				0 ng/ml	0 ng/ml
	Two-dimensional GC-GC/MS	0.002	THC-COOH				0 ng/ml	0 ng/ml
Cone et al. (2014); Cone et al. (2015)								
Urine (Session I)	GC/MS	15	THC-COOH	Before session, at end of exposure period, and at 0.25, 1, 2, 3, 4 h, then for the following time intervals: 4–6, 6–8, 8–10, 10–12, 12–22, 22–26, 26–30, and 30–34 h (urine pooled for each subject)	84	30–34 h	1.5 ng/ml ^d	22.4 ng/ml at 4–6 h after exposure ^d
	EMIT	20	THC				29.7 ng/ml	86.5 ng/ml at 4–6h after exposure
		50	Cannabinoids				Negative	Negative

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
Oral Fluid (OF) (Session I)	ELISA	4	Cannabinoids	Immediately prior to each session and following 1-h exposure session at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 22, 26, 30, and 34 h after end of exposure	102	34 h	Negative	Positive at 15 min (all subjects); mean (range) 1.25 (0.25–3) h after exposure
	LC/MS/MS	2	THC				0 ng/ml	34 ng/ml at 0.25h
		0.02	THC-COOH (total)				0 ng/ml	0 ng/ml
Whole blood (Session I)	LC/MS/MS	0.5	THC	Before session, at end of 1-h exposure session, and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 22, 26, 30, and 34 h after end of each exposure session	96 h	34 h	0 ng/ml	1.4 ng/ml at 0.25h
			THC-COOH (free)				0 ng/ml	1.2 ng/ml at 0.25h
			11-OH-THC				0 ng/ml	Negative
Urine (Session II)	GC/MS	15	THC-COOH	Before session, at end of exposure period, at 0.25, 1, 2, 3, 4 h, and then for following time intervals: 4–6, 6–8, 8–10, 10–12, 12–22, 22–26, 26–30, and 30–34 h (urine pooled for each subject)	84	30-34 h	6.5 ng/ml ^d	33.3 ng/ml at 4 h after exposure ^d
	EMIT	20	THC				44.8 ng/ml	140 ng/ml at 4 h after exposure
	50	Cannabinoids		Negative			A single presumptive positive result at 4 h after exposure	
Oral Fluid (OF) (Session II)	ELISA	4	Cannabinoids	Immediately prior to each session and following 1-h exposure session at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 22, 26, 30, and 34 h	102	34 h	Negative	Positive at 15 min (all subjects); mean (range) 1.38 (0.25-3) h after exposure
	LC/MS/MS	2	THC				0 ng/ml	81.5 ng/ml at 0.25h
		0.02	THC-COOH (total)				0 ng/ml	0 ng/ml
Whole blood (Session II)	LC/MS/MS	0.5	THC	Before session and following 1-h exposure session at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 22, 26, 30, and 34 h	96	34 h	0 ng/ml	3.1 ng/ml at 0.25h
			THC-COOH (free)				0 ng/ml	2.5 ng/ml at 0.25h

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
Urine (Session III)	GC/MS	15	11-OH-THC THC-COOH	Before session, at end of exposure period, and at 0.25, 1, 2, 3, 4 h, then for the following time intervals: 4–6, 6–8, 8–10, 10–12, 12–22, 22–26, 26–30, and 30–34 h (urine pooled for each subject)	84	30-34 h	0 ng/ml	Negative
	EMIT	20	THC				26.3 ng/ml	55.2 ng/ml at 4–6 h after exposure
		50	Cannabinoids				Negative	Negative
Oral Fluid (OF) (Session III)	ELISA	4	Cannabinoids	Immediately prior to each session and following the 1-h exposure session at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 22, 26, 30 and 34 h	102	34 h	Negative	Mean (range) 0.38 (0.25–1.5) h after exposure
	LC/MS/MS	2	THC				0 ng/ml	16.9 ng/ml at 0.25h
		0.02	THC-COOH (total)				0 ng/ml	0 ng/ml
Whole blood (Session III)	LC/MS/MS	0.5	THC	Before session and following the 1-h exposure session at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 22, 26, 30, and 34 h	96	34 h	0 ng/ml	0.5 ng/ml at 0.25 h
			THC-COOH (free)				0 ng/ml	0.2 ng/ml at 0.25 h
			11-OH-THC				0 ng/ml	Negative
Moosmann et al. (2014)								
Hair	LC/MS/MS	NA	THC-A	Before exposure period, 2 strands every week after the weekend (shortly before exposure to joint), and 2 strands 4 weeks after the exposure period. One participant gave 4 strands for seven weeks after the exposure period	30 strands of hair from various regions of the head	4 weeks after exposure for two participants and 7 weeks after exposure for one participant	0 pg/mg	17.3 pg/mg at the end of exposure period
		20 pg/mg	THC				50 pg/mg	803 pg/mg at the end of exposure period
		20 pg/mg	Cannabinol				36.7 pg/mg	307 pg/mg at the end of exposure period
Urine	EMIT	10	THC-COOH	Before exposure period, and	NA	NA	0 ng/ml	0 ng/ml

Body fluid	Analytical method	Cut-off (ng/ml)	Substances analyzed	Sampling scenario	Total number of samples	Last sample collection	Value of last collected samples	Maximum concentration obtained after exposure ^a
				twice a week				

ADx, Abbott automated method; Cigs, cigarettes; EIA, Enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; EMIT, enzyme multiplied immunoassay technique; GC/MS: Gas chromatography–mass spectrometry; LC/MS/MS, liquid chromatography–tandem mass spectrometry; NA, Information not available; RIA, Radioimmunoassay; THC, Δ^9 -tetrahydrocannabinol; THC-A, Δ^9 -tetrahydrocannabinolic acid A; THC-COOH, 11-nor-delta-9-THC-carboxylic acid; 11-OH-THC, 11-hydroxy-delta-9-THC.

^a The maximal concentration obtained in calculating a mean between the non-smoker values at a specific time.

^b In study I, volunteers were passively exposed to hashish smoke.

^c In study II, volunteers were passively exposed to marijuana smoke.

^d Urine values were adjusted for creatinine.

Table 2 Summary of the exposure scenarios of studies on the passive inhalation of cannabis smoke

Exposure area's volume (L)	Room type	Room ventilation	Substance	Smoking mode	Exposure smoke type	Protective equipment used	Specific exposure conditions	Placebo exposure	Non-smoking subject exposed	Gender	Age (years)	Exposure time (min)	Total exposure number	Exposure time period	No. of cannabis cigarettes smoked	THC dose (mg)
Perez-Reyes et al. (1983)																
15,500 ^a	Small room	Unventilated	Marijuana	Smokers (n = 4) ^b	Sidestream	None	None	None	2	3 F / 3 M	NA	60	1	NA	8 ^b	46
15,500 ^a	Small room	Unventilated	Marijuana	Smokers (n = 4) ^c	Sidestream	None	None	None	2	3 F / 3 M	NA	60	1	NA	8 ^c	52
3,500	Station wagon	Unventilated	Marijuana	Smokers (n = 4) ^c	Sidestream	None	None	None	2	3 F / 3 M	NA	60	1	NA	8 ^c	52
15,500	Small room	Unventilated	Marijuana	Smokers (n = 4) ^d	Sidestream	None	None	None	2	3 F / 3 M	NA	60	3	NA	4 ^d	105
Mason et al.(1983)																
15,500	Small room	unventilated	Marijuana	Smokers (n = 4) ^e	Sidestream	None	All analyses were performed blind	None	3 ^f	Males	NA	60	1	NA	4 ^e	105
Law et al. (1984)																
27,950	small office	Unventilated ^g	Cannabis resin	Smokers (n = 6) ^h	Sidestream	None	None	None	4	Males	NA	180	1	NA	6 ^h	103
Morland et al.(1985)																
1,650	Small car	NA	Hashish	Smokers (n = 3)	Sidestream	None	None	None	2	3 F / 7 M ⁱ	35–50	30	1	NA	6	90
1,650	Small car	NA	Marijuana	Smokers (n = 2)	Sidestream	None	None	None	3	3 F / 7 M ⁱ	35–50	30	1	NA	12	90
Cone and Johnson (1986); Cone et al. (1987a); Cone et al. (1987b)																
≈12,226 ^j	Closed ward under close surveillance	Small unventilated room	Marijuana	Machine	Only sidestream smoke (mainstream was removed)	Goggles ^k Not allowed to drink or eat during exposure sessions.	At rest. Double-blind conditions to the smoke	Yes ^l	5 (healthy drug-free with a history of Marijuana use)	Males	22, 26, 33, 40 and 54	60	12 (6 consecutive days per exposure)	Morning (8:30 to 9:30 am)	16 ^m	393.98 ⁿ
≈12,226 ^j	Closed ward under close surveillance	Small unventilated room	Marijuana	Machine	Only sidestream smoke (mainstream was removed)	Goggles ^k Not allowed to drink or eat during exposure sessions.	At rest Without blind conditions	None	2 (healthy drug-free with no history of Marijuana use, from staff)	Males	37 and 42	60	6 (6 consecutive days)	Morning (8:30 to 9:30 am)	16	2.8% Δ-9-THC

Exposure area's volume (L)	Room type	Room ventilation	Substance	Smoking mode	Exposure smoke type	Protective equipment used	Specific exposure conditions	Placebo exposure	Non-smoking subject exposed	Gender	Age (years)	Exposure time (min)	Total exposure number	Exposure time period	No. of cannabis cigarettes smoked	THC dose (mg)
Mule et al (1988)																
21,600	room	Windowless	Marijuana	Smokers (n = 8)	Sidestream	None	None	None	3	Males	NA	60	1	NA	4	108
Palmeri et al. (1995)																
30,780	room	unventilated	Hashish	machine	Sidestream	None	None	None	3	2 F / 2 M	30–50	60	1	NA	3	45
3,000	Car	Car windows closed	Hashish	machine	Sidestream	None	None	None	3	2 F / 2 M	30–50	30	1	NA	2	30
Niedbala et al. (2001)																
≈133,960	Room	No central ventilation system, but windows were opened occasionally to relieve the smoky atmosphere	Marijuana	Smokers (n = 10) ^p	Sidestream	None	Drinking beer or soda during exposure was allowed. Food (pizza) was available after first 2 h of specimen collection ^q	None	2 (control subjects)	Males	32 and 39	240	1	NA	10 ^p	NA
Niedbala et al. (2004)																
36,000	Room	A closed room with all door and window openings sealed	Marijuana	Smokers (n = 5) ^f	Sidestream	None No drinking allowed for first 60 min.	Located approx.. 1.5 m from smokers	None	4	Males	37–49	240 (4h)	1	NA	5 ^f	NA
Niedbala et al. (2005)																
Study 1 15,300	Motor vehicle (8 passengers)	Unventilated (doors and windows closed, and engine turned off)	Marijuana	Smokers (n = 4) ^s	Sidestream	None	Seat ^t	None	4	Males	34–50	60	1	NA	4 ^s	158 ^s
Study 2 15,300	Motor vehicle (8 passengers)	Unventilated (doors and windows closed, and engine turned off)	Marijuana	Smokers (n = 4) ^u	Sidestream	None	Seat ^t	None	4	Males	25–50	60	1	NA	4 ^u	333 ^u

Exposure area's volume (L)	Room type	Room ventilation	Substance	Smoking mode	Exposure smoke type	Protective equipment used	Specific exposure conditions	Placebo exposure	Non-smoking subject exposed	Gender	Age (years)	Exposure time (min)	Total exposure number	Exposure time period	No. of cannabis cigarettes smoked	THC dose (mg)
Rohrich et al. (2010)																
200,000	Coffee shop (large room)	No windows but relatively efficient ventilation; not very smoky during the exposure period.	Cannabis cigarettes Additional 8 g hashish and marijuana was burned down by the volunteers in an ashtray about 1.5 m away from them.	Smokers (n = 8 to 25) stayed around 15 min, but some up to 1h. Not less than 1 m from passive smokers, mostly 5 to 6 m away.	Sidestream	None	Volunteers sat together at a table almost in middle of room. Each volunteer consumed 2 to 3 cans (0.33 L) of soft drinks (no food)	None	8	4 F / 4 M	28–49	180	1	NA	8–25 smoking guests ^v	^v
Schimmel et al. (2010)																
200,000	Coffee shop	Yes (no window)	Hashish and marijuana	Smokers (n = 8 to 25)	Sidestream	NA	NA	None	8	4 F / 4 M	27–59	180	1	NA	NA	8 g of hashish and marijuana were burnt
Moore et al. (2011)																
Place 1: 122,500	Coffee shop (large room)	NA	Marijuana	Smokers (n = 4 to 16; mean: 8)	Sidestream	None	NA	None	10	3 F / 2 M	22.5–23	180	1	NA	4–16 active smokers	NA
Place 2: 42,000	Coffee shop (small room)	NA	Marijuana	Smokers (n = 0 to 6; mean: 2.5)	Sidestream	None	NA	None	10	3 F / 2 M	23–25	180	1	NA	0–6 active smokers	NA
Cone et al. (2014, 2015)																
≈ 25,726	Exposure chamber ^w	Unventilated	Cannabis	Smokers ^x	Sidestream	Goggles	Non-smokers remained in their assigned	None	6	9 F / 9 M in total	Av. age 28 (7x 20–45)	60	1	NA	<i>Ad libitum</i>	5,3% ^x
≈ 25,726	Exposure chamber ^w	Unventilated (the door was opened briefly)	Cannabis	Smokers ^y	Sidestream	Goggles	Non-smokers remained in their assigned	None	6			60	1	NA	<i>Ad libitum</i>	11,3% ^y

Exposure area's volume (L)	Room type	Room ventilation	Substance	Smoking mode	Exposure smoke type	Protective equipment used	Specific exposure conditions	Placebo exposure	Non-smoking subject exposed	Gender	Age (years)	Exposure time (min)	Total exposure number	Exposure time period	No. of cannabis cigarettes smoked	THC dose (mg)
≈ 25,726	Exposure chamber ^w	for exit and entry) Ventilated (comparable to home air-conditioning (11.2 air changes per hour)	Cannabis		Sidestream	Goggles	seats. Not allowed to eat or drink during or after session until after first oral fluid specimen collected.	None	6			60	1	NA	<i>Ad libitum</i>	11,3% ^y
Moosmann et al. (2014)																
12,500	Room	NA	Marijuana	Water-jet vacuum pump	Sidestream	Smoke inhalation excluded by breathing compressed air through SCUBA regulators	Non-smokers sat in a circle facing each other. Joint held in front participant's mouth for 10–15 s, then connected to vacuum for one puff, then passed on to next participant	None	3	NA	NA	15–20 minutes (one joint) every weekday for 3 weeks	15	Morning	1 every weekday for 3 weeks	500 mg of marijuana a flowers containing 9.2% THC ^z

F, female; M, males; NA, information not available.

^a The volume of solid furniture present in the room was subtracted from the total room volume.

^b Each smoker smoked 2 marijuana cigarettes containing 2.5% of THC.

^c Each smoker smoked 2 marijuana cigarettes containing 2.8% of THC. 2.8% is the highest potency marijuana cigarette available from NIDA (National Institute on Drug Abuse).

^d Each smoker smoked 4 marijuana cigarettes containing 2.8% of THC daily for 3 consecutive days. 2.8% is the highest potency marijuana cigarette available from NIDA.

^e Each cigarette contained 26.2 mg of THC.

^f Two non-smokers participated at the beginning of exposure; on the second day of study, a third passive smoker participated.

^g The single door was opened and closed approximately 18 times during the experiment to allow access to the subjects.

^h Cigarettes contained an average of 175 mg resin, equivalent to 17.1 mg THC per cigarette. The smoking period lasted 10–34 min.

ⁱ No information about the gender repartition between studies.

^j Volume adjusted for contents and the presence of 5 volunteers.

^k To minimize eye irritation and to prevent color discrimination between placebo and active cigarettes.

^l Before and after marijuana exposure, exposure to 16 placebo cigarettes in the same conditions for 2 days (1st exposure) and 1 day (2nd exposure) to 4 placebo cigarettes.

^m 8 cigarettes burnt from 8:30 to 8:45 am; and from 9:00 to 9:15 am 8 others for the 1st exposure; 4 cigarettes (and not 8) burnt for the 2nd exposure using the same exposure pattern.

ⁿ Cigarettes had an average weight of 877±20 mg.

^o There were in total 4 volunteers including 2 females and 2 males, and 3 of them have participated in each study.

^p Cigarettes contained an average of 20–25 mg THC. The smoking period was 20–30 min.

^q Collection of oral fluid specimens was preceded by a 10-min "time-out" period (no eating or drinking).

^r Joints contained an average of 1.75% THC per cigarette (\approx 12.75 mg of THC). The smoking period was 20 min.

^s Joints contained an average of 5.4% THC per cigarette (\approx 39.5 mg of THC mixed with tobacco). The smoking period was 20 min.

^t One cannabis smoker sat on each row alongside one passive subject.

^u Joints contained an average of 10.9% THC per cigarette (\approx 83.2 mg pure THC). The smoking period was 20 min.

^v The exact number of joints smoked during the 3 h period and the average THC content of the cannabis cigarettes is unknown. Additionally, 8 g of both hashish and marijuana was burned by the volunteers in an ashtray about 1.5 m away from them.

^w A specially designed smoking chamber made of Plexiglas walls and aluminum supports was built for this experiment.

^x The lower potency cannabis cigarettes were machine rolled to 85 mm in length, 25 mm in circumference, and weighed a mean 0.92 g/cigarette (SD = 0.06); the cigarettes had an assayed mean content of cannabinoids as follows: 5.3% (0.48%) total THC, 0.01% (0.0%) CBD, and 0.35% (0.04%) CBN.

^y The higher potency cigarettes were hand-rolled to 70 mm in length (24.5 mm) and had a mean weight of 1.0 g/cigarette (SD = 0.04); the cigarettes had an assayed mean content (n = 12 for THC; n = 4 for other cannabinoids) of cannabinoids as follows: 11.3% (0.29%) total THC, 0.08% (0.12%) CBD, and 0.76% (0.06%) CBN.

^z Each day, one joint was prepared using 500 mg marijuana flowers with a total THC content of 9.2% and 500 mg tobacco.

Acknowledgements

This work was supported by an internal grant from the University Department of Community Medicine and Health (DUMSC) of the University Hospital (CHUV) of Lausanne (Switzerland). The authors thank Darren Hart for his valuable comments and his assistance in revising the English text. They also acknowledge Dr Nancy Hopf for her suggestions and comments to improve the structure of the review.